STOCK TITAN

TAO Synergies posts $6.46M Q3 net income

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

TAO Synergies Inc. (TAOX) reported third-quarter TAO staking revenue of $245,724, compared with $203,371 a year earlier. Net income was $6,458,553, including an $8,324,666 unrealized gain on digital assets; net income attributable to common stockholders was $4,062,297 after preferred dividends and a $2,071,000 deemed dividend on Series E warrants.

For the nine months, staking revenue was $723,124 versus $207,333, and net income was $1,413,979 versus a net loss of $21,054,156. Net loss attributable to common stockholders was $5,544,706. At September 30, cash and equivalents were $1,281,239; digital assets had a $25,379,795 fair market value, representing 84,405 TAO, and a cumulative unrealized loss of $3,787,098. Operating cash used was $3,448,132.

The FDA placed development of the Fragile X investigational new drug application on clinical hold pending further pharmacokinetics and pharmacodynamics analytics; TAO Synergies said it was not conducting clinical trials. On October 21, 2026, it formed AlphaSynergies.ai to facilitate AI expansion using its cryptocurrency treasury strategy. As of November 16, 2026, it reported approximately 84,855 TAO with a market value of approximately $15.8 million.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointNine-month staking revenue was $723,124, compared with $207,333 in 2025.
  • Moderate pointNine-month net income was $1,413,979, versus a $21,054,156 net loss in 2025.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Fragile X IND is on clinical hold; estimated trial and IND cost is $2.0 million. 13% of market cap

Filing Explained

November thirteenth repricing set Series D and E warrant exercise prices to two dollars and ten cents per share; potential-share counts are dated September thirtieth.

At September 30, 2026, TAO Synergies reported 7,979,885 common shares outstanding and still had Series D and E preferred stock and warrants that could convert or be exercised into more common shares; if that happens, the larger share count would reduce existing holders’ percentage ownership.

The company reported 7,448,343 common shares outstanding at December 31, 2025, compared with 7,979,885 at September 30, 2026.

At September 30, 2026, 679 Series D shares were convertible into 226,187 common shares, and 9,053 Series E shares into 2,286,493; their associated warrants could purchase 349,667 and 2,971,433 shares, respectively.

On November 13, 2026, the company repriced Series D and Series E warrant exercise prices to $2.10 per share; the reported potential-share counts are dated September 30, 2026.

Third-quarter TAO staking revenue $245,724 Three months ended September 30, 2026; $203,371 in 2025.
Third-quarter net income $6,458,553 Three months ended September 30, 2026; net loss of $3,923,247 in 2025.
Nine-month TAO staking revenue $723,124 Nine months ended September 30, 2026; $207,333 in 2025.
Nine-month net income $1,413,979 Nine months ended September 30, 2026; net loss of $21,054,156 in 2025.
Cash and cash equivalents $1,281,239 As of September 30, 2026.
TAO holdings fair market value $25,379,795 84,405 tokens as of September 30, 2026.
Cumulative unrealized loss on TAO holdings $3,787,098 As of September 30, 2026.
Estimated Fragile X trial and IND cost $2.0 million Company estimate; development of the IND is on FDA clinical hold pending further analytics.
Yuma Consensus technical
"an algorithm named Yuma Consensus aggregates validators’ rankings"
variable consideration financial
"staking rewards represent variable consideration"
Amount of promised consideration in a contract whose final value depends on future events or uncertainties — for example discounts, rebates, performance bonuses, refunds, rights of return, or milestone payments. Under modern revenue-recognition rules (IFRS 15 / ASC 606) an entity estimates variable consideration using either the expected value or the most likely amount, then includes it in the transaction price only to the extent it is probable the estimate will not result in a significant reversal of cumulative revenue when the uncertainty is resolved. The estimate is updated as facts and circumstances change and the effect of any change is recognized in revenue.
fair value hierarchy financial
"classified as Level 1 within the fair value hierarchy"
embedded derivative liability financial
"fair value of the embedded derivative liability"
clinical hold medical
"FDA has placed the development of the IND on clinical hold"
A clinical hold is an order from a drug or medical-device regulator to stop or suspend a clinical trial or development activity because of safety concerns, inadequate study plans, or incomplete data. Think of it like a referee pausing a game until rules or safety issues are resolved; investors care because a hold can delay approval, increase costs, create uncertainty about a product’s future, and often affects a company’s valuation until the issues are addressed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net income did TAOX report for the third quarter of 2026?

For the three months ended September 30, 2026, TAOX reported $245,724 in TAO staking revenue and net income of $6,458,553, compared with $203,371 in revenue and a net loss of $3,923,247 in the same 2025 period. The company reported an $8,324,666 unrealized gain on digital assets.

How much TAO did TAOX hold at September 30, 2026?

TAOX reported 84,405 TAO with a fair market value of $25,379,795 as of September 30, 2026. The company also reported a cumulative unrealized loss of $3,787,098 on those holdings.

What is the status of TAOX’s Fragile X drug program?

The FDA placed development of the company’s Fragile X investigational new drug application on clinical hold pending further analytics relating to pharmacokinetics and pharmacodynamics. TAOX said it was not conducting clinical trials and estimated total trial and IND costs at approximately $2.0 million.

How much cash did TAOX report at September 30, 2026?

TAOX reported $1,281,239 in cash and cash equivalents at September 30, 2026. Net cash used in operating activities for the nine months ended that date was $3,448,132.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001571934--12-312026Q3false00TAO Synergies Inc.P3Yhttp://fasb.org/us-gaap/2026#UnrealizedGainLossOnInvestments0001571934taox:SeriesBWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-09-300001571934taox:SeriesBWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-09-300001571934taox:SeriesBWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-09-300001571934taox:SeriesBWarrantsMembertaox:MeasurementInputEstimatedEquityVolatilityMember2026-09-300001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-07-060001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-07-060001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-07-060001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-07-060001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-07-050001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-07-050001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-07-050001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-07-050001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-05-180001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-05-180001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-05-180001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-05-180001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-05-170001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-05-170001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-05-170001571934taox:SeriesEWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-05-170001571934taox:SeriesBWarrantsMember2026-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2026-07-012026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2026-07-012026-09-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2026-09-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2025-10-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-06-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-06-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2025-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2025-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-06-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-06-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2024-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2025-01-012025-09-300001571934us-gaap:RestrictedStockMember2026-09-082026-09-080001571934us-gaap:RestrictedStockMember2026-01-162026-01-160001571934us-gaap:CommonStockMember2026-07-012026-09-300001571934us-gaap:CommonStockMember2026-01-012026-09-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMember2025-01-012025-09-300001571934us-gaap:RetainedEarningsMember2026-09-300001571934us-gaap:AdditionalPaidInCapitalMember2026-09-300001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300001571934us-gaap:RetainedEarningsMember2026-06-300001571934us-gaap:AdditionalPaidInCapitalMember2026-06-300001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-3000015719342026-06-300001571934us-gaap:RetainedEarningsMember2025-12-310001571934us-gaap:AdditionalPaidInCapitalMember2025-12-310001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001571934us-gaap:RetainedEarningsMember2025-09-300001571934us-gaap:AdditionalPaidInCapitalMember2025-09-300001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001571934us-gaap:RetainedEarningsMember2025-06-300001571934us-gaap:AdditionalPaidInCapitalMember2025-06-300001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-3000015719342025-06-300001571934us-gaap:RetainedEarningsMember2024-12-310001571934us-gaap:AdditionalPaidInCapitalMember2024-12-310001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001571934us-gaap:CommonStockMember2026-09-300001571934us-gaap:CommonStockMember2026-06-300001571934us-gaap:CommonStockMember2025-12-310001571934us-gaap:CommonStockMember2025-09-300001571934us-gaap:CommonStockMember2025-06-300001571934us-gaap:CommonStockMember2024-12-3100015719342025-01-012025-12-310001571934taox:SubsidiaryStockAwardsMemberus-gaap:SubsequentEventMember2026-11-162026-11-160001571934taox:RobertWeinsteinChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMembertaox:EquityIncentivePlan2020Memberus-gaap:CommonStockMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001571934taox:JoshuaSilvermanExecutiveChairmanMemberus-gaap:EmployeeStockOptionMembertaox:EquityIncentivePlan2020Memberus-gaap:CommonStockMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001571934taox:JoshuaSilvermanExecutiveChairmanMemberus-gaap:StockCompensationPlanMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001571934taox:RobertWeinsteinChiefExecutiveOfficerMembertaox:SubsidiaryStockAwardsMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001571934taox:JoshuaSilvermanExecutiveChairmanMembertaox:SubsidiaryStockAwardsMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001571934taox:JamesAltucherConsultantMembertaox:SubsidiaryStockAwardsMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001571934taox:BruceTBernsteinMembertaox:SubsidiaryStockAwardsMemberus-gaap:SubsequentEventMember2026-11-132026-11-130001571934taox:DirectorsAndOfficersMember2026-05-182026-05-180001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2025-04-072025-04-070001571934taox:EquityIncentivePlan2020Member2024-12-060001571934taox:EquityIncentivePlan2020Member2024-12-050001571934taox:EquityIncentivePlan2020Member2023-12-200001571934taox:EquityIncentivePlan2020Member2023-12-1900015719342025-08-0600015719342025-08-050001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-290001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-290001571934taox:EquityIncentivePlan2020Memberus-gaap:SubsequentEventMember2026-11-130001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2026-05-182026-05-180001571934us-gaap:RestrictedStockMembertaox:ConsultingAgreementWithSherwoodVenturesLlcMember2026-06-082026-06-080001571934us-gaap:RestrictedStockMember2026-03-062026-03-060001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-03-292023-03-290001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-03-292023-03-290001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-292023-03-290001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-292023-03-290001571934srt:MinimumMember2026-09-300001571934srt:MaximumMember2026-09-300001571934taox:ConsultingAgreementMember2026-07-012026-09-300001571934taox:ConsultingAgreementMember2026-01-012026-09-300001571934taox:ConsultingAgreementMember2025-07-012025-09-300001571934taox:ConsultingAgreementMember2025-01-012025-09-300001571934taox:AgreementsWithBryologyxMember2020-06-092020-06-090001571934taox:AgreementsWithBryologyxMember2026-01-012026-09-300001571934us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2026-09-300001571934us-gaap:FairValueInputsLevel3Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueMeasurementsRecurringMember2026-09-300001571934us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001571934us-gaap:FairValueInputsLevel3Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2026-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2026-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2026-09-300001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2026-06-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2026-06-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2026-06-300001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2025-12-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2025-12-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2025-12-310001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2025-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2025-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2025-09-300001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2025-06-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2025-06-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2025-06-300001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2024-12-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2024-12-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2024-12-310001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2026-07-012026-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2026-07-012026-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2026-07-012026-09-300001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2026-01-012026-09-300001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2025-07-012025-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2025-07-012025-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2025-07-012025-09-300001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2025-01-012025-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2025-01-012025-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2025-01-012025-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2026-01-012026-09-300001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2026-01-012026-09-300001571934taox:SeriesBWarrantsMemberus-gaap:WarrantMember2026-01-012026-09-300001571934taox:SeriesBWarrantsMember2026-07-012026-09-300001571934taox:SeriesBWarrantsMember2026-01-012026-09-300001571934taox:SeriesBWarrantsMember2025-07-012025-09-300001571934taox:SeriesBWarrantsMember2025-01-012025-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2025-07-012025-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2025-07-012025-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2025-01-012025-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2025-01-012025-09-300001571934us-gaap:RetainedEarningsMember2025-07-012025-09-3000015719342026-11-160001571934taox:UnStakedTaoMember2026-09-300001571934taox:StakedTaoMember2026-09-300001571934us-gaap:LicenseMembertaox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2026-07-012026-09-300001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2026-07-012026-09-300001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2026-01-012026-09-300001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2026-01-012026-09-300001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-07-012025-09-300001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2025-07-012025-09-300001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-01-012025-09-300001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2025-01-012025-09-300001571934taox:SeriesBBrokerWarrantsMember2022-11-170001571934taox:ZListMediaInc.Membertaox:SeriesEWarrantsMemberus-gaap:SubsequentEventMember2026-11-130001571934taox:ZListMediaInc.Membertaox:SeriesDWarrantsMemberus-gaap:SubsequentEventMember2026-11-130001571934taox:ThirdTrancheWarrantsMembertaox:ConsultingAgreementAmendmentMemberus-gaap:SubsequentEventMember2026-11-130001571934taox:SecondTrancheWarrantsMembertaox:ConsultingAgreementAmendmentMemberus-gaap:SubsequentEventMember2026-11-130001571934taox:FourthTrancheWarrantsMembertaox:ConsultingAgreementAmendmentMemberus-gaap:SubsequentEventMember2026-11-130001571934taox:FirstTrancheWarrantsMembertaox:ConsultingAgreementAmendmentMemberus-gaap:SubsequentEventMember2026-11-130001571934taox:ZListMediaInc.Memberus-gaap:SubsequentEventMember2026-11-130001571934taox:SeriesEWarrantsMember2026-07-0600015719342026-07-060001571934taox:SeriesEWarrantsMember2026-07-050001571934taox:SeriesEWarrantsMember2026-05-180001571934taox:SeriesEWarrantsMember2026-05-170001571934taox:ThirdTrancheWarrantsMembertaox:AltucherConsultingAgreementMember2025-06-080001571934taox:SecondTrancheWarrantsMembertaox:AltucherConsultingAgreementMember2025-06-080001571934taox:FourthTrancheWarrantsMembertaox:AltucherConsultingAgreementMember2025-06-080001571934taox:FirstTrancheWarrantsMembertaox:AltucherConsultingAgreementMember2025-06-0800015719342025-09-3000015719342024-12-310001571934us-gaap:WarrantMember2026-07-012026-09-300001571934us-gaap:EmployeeStockOptionMember2026-07-012026-09-300001571934us-gaap:WarrantMember2026-01-012026-09-300001571934us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001571934us-gaap:ConvertiblePreferredStockMember2026-01-012026-09-300001571934us-gaap:WarrantMember2025-07-012025-09-300001571934us-gaap:EmployeeStockOptionMember2025-07-012025-09-300001571934us-gaap:ConvertiblePreferredStockMember2025-07-012025-09-300001571934us-gaap:WarrantMember2025-01-012025-09-300001571934us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001571934us-gaap:ConvertiblePreferredStockMember2025-01-012025-09-300001571934taox:StockOptionsAndRestrictedStockUnitsMember2026-07-012026-09-300001571934taox:StockOptionsAndRestrictedStockUnitsMember2026-01-012026-09-300001571934taox:StockOptionsAndRestrictedStockUnitsMember2025-07-012025-09-300001571934taox:StockOptionsAndRestrictedStockUnitsMember2025-01-012025-09-300001571934us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001571934us-gaap:AdditionalPaidInCapitalMember2026-01-012026-09-300001571934taox:Mt.SinaiLicenseAgreementMember2026-09-300001571934taox:Mt.SinaiLicenseAgreementMember2026-02-242026-02-240001571934taox:SeriesCConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2026-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2026-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2026-01-012026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2026-01-012026-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2025-10-012025-10-310001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2025-01-012025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2025-01-012025-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2025-01-012025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2026-07-012026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2026-07-012026-09-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2026-07-012026-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2026-01-012026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2026-01-012026-09-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2026-01-012026-09-300001571934us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001571934us-gaap:CommonStockMember2025-07-012025-09-300001571934us-gaap:CommonStockMember2025-01-012025-09-300001571934srt:MinimumMembertaox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934srt:MaximumMembertaox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934taox:NetSalesUpToDollars250MillionMembertaox:Mt.SinaiLicenseAgreementMember2014-07-142014-07-140001571934taox:NetSalesOverDollarsMillionMembertaox:Mt.SinaiLicenseAgreementMember2014-07-142014-07-140001571934taox:SingleReportableSegmentMember2026-07-012026-09-300001571934taox:SingleReportableSegmentMember2026-01-012026-09-300001571934taox:SingleReportableSegmentMember2025-07-012025-09-300001571934taox:SingleReportableSegmentMember2025-01-012025-09-300001571934taox:DanielLAlkonMembertaox:AlkonConsultingAgreementMemberus-gaap:RelatedPartyMember2025-08-090001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2025-06-080001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-06-060001571934taox:DanielLAlkonMembertaox:AlkonConsultingAgreementMemberus-gaap:RelatedPartyMember2025-06-040001571934taox:ConsultingAgreementMember2026-09-300001571934us-gaap:RetainedEarningsMember2026-07-012026-09-300001571934us-gaap:RetainedEarningsMember2026-01-012026-09-300001571934taox:AgreementsWithBryologyxMember2020-06-090001571934taox:CognitiveResearchEnterprisesIncMember2026-01-012026-09-3000015719342026-05-182026-05-180001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2026-04-072026-04-070001571934taox:Mt.SinaiLicenseAgreementMember2026-01-012026-09-300001571934taox:StanfordLicenseAgreementsMember2014-05-122014-05-120001571934taox:Mt.SinaiLicenseAgreementMember2014-07-142026-09-300001571934taox:YumaSubnetCompositeOnshoreFundL.p.Member2025-10-240001571934taox:YumaLargeCapSubnetOnshoreFundL.p.Member2025-10-240001571934taox:July2026AdjustmentMembertaox:SeriesEWarrantsMember2026-07-012026-09-300001571934taox:May2026AdjustmentMembertaox:SeriesEWarrantsMember2026-01-012026-09-300001571934taox:July2026AdjustmentMembertaox:SeriesEWarrantsMember2026-01-012026-09-3000015719342026-11-162026-11-160001571934srt:MinimumMember2025-09-012025-09-300001571934srt:MaximumMember2025-09-012025-09-3000015719342025-07-012025-09-300001571934us-gaap:SubsequentEventMember2026-11-130001571934us-gaap:SubsequentEventMember2026-11-300001571934taox:UnStakedTaoMember2026-01-012026-09-300001571934taox:StakedTaoMember2026-01-012026-09-300001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-08-142025-08-140001571934taox:JoshuaSilvermanMembertaox:IfTerminationOccursWithin2YearsOr6MonthsPrecedingChangeOfControlMemberus-gaap:RelatedPartyMember2025-08-140001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-08-140001571934taox:StanfordLicenseAgreementsMember2026-01-012026-09-300001571934taox:NemoursAgreementMember2021-08-052021-08-050001571934taox:NemoursAgreementMember2026-01-012026-09-300001571934taox:SeriesEWarrantsMember2026-07-062026-07-060001571934taox:SeriesEWarrantsMember2026-05-182026-05-1800015719342026-09-3000015719342025-12-310001571934taox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934us-gaap:RetainedEarningsMember2025-01-012025-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-300001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-300001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-09-300001571934taox:SeriesCConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-09-300001571934us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-3000015719342025-01-012025-09-300001571934taox:Mt.SinaiLicenseAgreementMember2014-07-1400015719342026-07-012026-09-3000015719342026-11-1300015719342026-01-012026-09-30xbrli:sharesiso4217:USDxbrli:puretaox:itemiso4217:USDxbrli:sharestaox:agreementtaox:Votetaox:segmenttaox:Y
Table of Contents

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 10-Q

​

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

​

or

​

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

​

For the transition period from __________________ to __________________

​

Commission File Number: 001-40458

​

TAO SYNERGIES INC.

(Exact name of registrant as specified in its charter)

​

Delaware

46-1585656

(State or other jurisdiction of incorporation or

(I.R.S. Employer

organization)

Identification No.)

1185 Avenue of the Americas, 3rd Floor

​

New York, New York

10036

(Address of principal executive offices)

(Zip code)

​

(973) 242-0005

(Registrant’s telephone number, including area code)

​

N/A

​

(Former name, former address and former fiscal year, if changed since last report)

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of each exchange on
which registered

​

​

​

​

​

​

Common Stock, $0.0001 par value per share

  ​ ​ ​

TAOX

  ​ ​ ​

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

​

As of November 13, 2026, there were 8,044,885 shares of the registrant’s common stock, $0.0001 par value per share, issued and outstanding.

​

​

​

​

Table of Contents

​

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan,” “anticipate,” “believe,” “estimate,” “should,” “expect” and similar expressions, include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our inability to obtain adequate financing, fluctuations in the price of our digital assets, potential decreases in the value of our digital assets and rewards, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, our inability to expand our business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, volatility in the price of our raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and our failure to implement our business plans or strategies. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. You should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026, as updated in our quarterly reports and current reports filed with the SEC from time to time. We advise you to carefully review the reports and documents we file from time to time with the SEC including our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under securities laws, we undertake no obligation to publicly release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

​

​

2

Table of Contents

​

TABLE OF CONTENTS

​

Page

Part I – FINANCIAL INFORMATION

4

 

Item 1. Financial Statements (Unaudited)

4

 

Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025

4

 

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2026 and 2025

5

 

Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025

6

 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025

8

 

Notes to Condensed Consolidated Financial Statements

9

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

31

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

41

 

Item 4. Controls and Procedures

41

 

Part II – OTHER INFORMATION

42

 

Item 1. Legal Proceedings

42

 

Item 1A. Risk Factors

42

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

51

 

Item 3. Defaults upon Senior Securities

52

 

Item 4. Mine Safety Disclosures

52

 

Item 5. Other Information

53

 

Item 6. Exhibits

55

 

Signatures

56

​

​

​

3

Table of Contents

​

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements.

TAO SYNERGIES INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

​

​

​

​

​

​

​

​

ASSETS

  ​ ​ ​

​

​

  ​ ​ ​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

​

​

​

​

CURRENT ASSETS

​

​

​

​

​

​

Cash and cash equivalents

​

$

1,281,239

​

$

5,497,671

Digital assets

​

​

25,379,795

​

​

17,927,183

Prepaid expenses and other current assets

​

 

902,309

​

​

1,953,904

​

​

​

​

​

​

​

TOTAL CURRENT ASSETS

​

 

27,563,343

​

 

25,378,758

​

​

​

​

​

​

​

Fixed assets, net of accumulated depreciation

​

​

7,023

​

​

9,309

Yuma Partnership investments

​

 

757,532

​

 

446,954

​

​

 

​

​

 

​

TOTAL ASSETS

​

$

28,327,898

​

$

25,835,021

​

​

 

  ​

​

 

  ​

​

​

 

  ​

​

 

  ​

LIABILITIES AND STOCKHOLDERS’ EQUITY

​

 

  ​

​

 

  ​

​

​

 

  ​

​

 

  ​

CURRENT LIABILITIES

​

 

  ​

​

 

  ​

Accounts payable

​

$

977,542

​

$

1,175,323

Accrued expenses

​

 

158,894

​

 

638,516

​

​

 

​

​

 

​

TOTAL CURRENT LIABILITIES

​

 

1,136,436

​

 

1,813,839

​

​

​

​

​

​

​

Warrant liability

​

​

10,000

​

​

9,000

Derivative liability

​

​

3,239,000

​

​

2,114,000

​

​

​

​

​

​

​

TOTAL LIABILITIES

​

​

4,385,436

​

​

3,936,839

​

​

 

  ​

​

 

  ​

Commitments and contingencies

​

 

  ​

​

 

  ​

​

​

 

  ​

​

 

  ​

Series D Convertible redeemable preferred stock, $.0001 par value and $1,000 face value, 1,000,000 shares authorized; 678.562 shares issued and outstanding at September 30, 2026 and December 31, 2025. Liquidation preference of $678,562 plus dividends accrued at 5% per annum of $0 as of September 30, 2026.

​

​

686,026

​

​

507,927

​

​

​

​

​

​

​

Series E Convertible redeemable preferred stock, $.0001 par value and $1,000 face value, 1,000,000 shares authorized; 9,053 and 11,000 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively. Liquidation preference of $9.05 million plus dividends accrued at 7% per annum of $188,642 as of September 30, 2026.

​

​

4,187,535

​

​

338,774

​

​

​

​

​

​

​

​

​

​

​

​

​

​

STOCKHOLDERS’ EQUITY

​

​

​

​

​

​

Common stock - 150,000,000 shares authorized, $0.0001 par value; 7,979,885 shares issued and outstanding as of September 30, 2026 and 7,448,343 shares issued and outstanding as of December 31, 2025.

​

​

799

​

​

746

Additional paid-in capital

​

​

94,575,101

​

​

97,242,028

Accumulated other comprehensive income

​

​

5,702

​

​

5,702

Accumulated deficit

​

​

(75,512,701)

​

​

(76,196,995)

​

​

​

​

​

​

​

TOTAL STOCKHOLDERS’ EQUITY

​

 

19,068,901

​

 

21,051,481

​

​

​

​

​

​

​

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

​

$

28,327,898

​

$

25,835,021

​

See accompanying notes to these Condensed Consolidated financial statements.

​

4

Table of Contents

​

TAO SYNERGIES INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three Months Ended

  ​ ​ ​

Three Months Ended

  ​ ​ ​

Nine Months Ended

  ​ ​ ​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

September 30, 

​

September 30, 

​

​

2026

​

2025

​

2026

​

2025

REVENUES:

​

​

​

​

​

​

​

​

​

​

​

​

Revenues from TAO staking

​

$

245,724

​

$

203,371

​

$

723,124

​

$

207,333

​

​

​

​

​

​

​

​

​

​

​

​

​

OPERATING EXPENSES:

​

​

​

​

​

​

​

​

​

​

​

​

Research and development

 

​

29,814

​

​

54,388

​

​

90,269

​

​

263,759

General and administrative

 

​

1,900,816

​

 

1,948,483

​

 

5,204,761

​

 

5,148,227

Warrant issuance costs

​

​

—

​

​

—

​

​

—

​

​

699,845

TOTAL OPERATING EXPENSES

 

​

1,930,630

​

 

2,002,871

​

 

5,295,030

​

 

6,111,831

​

 

​

  ​

​

 

  ​

​

 

​

​

 

​

OPERATING LOSS

​

​

(1,684,906)

​

​

(1,799,500)

​

​

(4,571,906)

​

​

(5,904,498)

​

​

​

​

​

​

​

​

​

​

​

​

​

OTHER INCOME (EXPENSE):

 

​

​

​

​

​

​

​

​

​

​

​

Interest income

 

​

11,085

​

 

43,292

​

 

71,819

​

 

378,424

Unrealized gain (loss) on digital assets

​

​

8,324,666

​

​

(2,382,129)

​

​

6,729,488

​

​

(2,396,497)

Change in fair value of Yuma partnership investments

​

​

278,708

​

​

—

​

​

310,578

​

​

—

Change in fair value of warrant liability

​

​

(1,000)

​

​

109,090

​

​

(1,000)

​

​

(13,055,585)

Change in fair value of derivative liability

​

​

(470,000)

​

​

106,000

​

​

(1,125,000)

​

​

(76,000)

TOTAL OTHER INCOME (EXPENSE)

 

​

8,143,459

​

 

(2,123,747)

​

 

5,985,885

​

 

(15,149,658)

​

​

​

​

​

​

​

​

​

​

​

​

​

Net income (loss) before income taxes

 

​

6,458,553

​

 

(3,923,247)

​

 

1,413,979

​

 

(21,054,156)

​

 

​

​

​

 

​

​

 

​

​

 

​

Provision for income taxes

 

​

—

​

 

—

​

 

—

​

 

—

​

​

​

​

​

​

​

​

​

​

​

​

​

Net income (loss)

​

​

6,458,553

​

​

(3,923,247)

​

​

1,413,979

​

​

(21,054,156)

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred Stock dividends

​

​

325,256

​

​

45,210

​

​

729,685

​

​

249,352

Deemed dividend on Series E Warrants

​

​

2,071,000

​

​

—

​

​

6,229,000

​

​

—

​

 

​

​

​

 

​

​

 

​

​

 

​

Net income (loss) attributable to common stockholders

​

$

4,062,297

​

$

(3,968,457)

​

$

(5,544,706)

​

$

(21,303,508)

​

​

​

​

​

​

​

​

​

​

​

​

​

PER SHARE DATA:

​

 

​

​

 

​

​

 

​

​

 

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic income (loss) per common share

​

$

0.38

​

$

(1.56)

​

$

(0.74)

​

$

(9.84)

Fully diluted income (loss) per common share

​

$

0.38

​

$

(1.56)

​

$

(0.74)

​

$

(9.84)

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic weighted average common shares outstanding

​

 

7,538,500

​

 

2,549,600

​

 

7,493,400

​

 

2,164,500

Fully diluted weighted average common shares outstanding

​

​

7,590,053

​

​

2,549,600

​

​

7,493,400

​

​

2,164,500

​

See accompanying notes to these Condensed Consolidated financial statements.

​

5

Table of Contents

​

TAO SYNERGIES INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three Months Ended September 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Additional

​

​

​

​

Accumulated Other

​

​

​

​

​

Series C Preferred Stock

​

Series D Preferred Stock

​

Series E Preferred Stock

​

​

Common Stock

​

Paid-In

​

Accumulated

​

Comprehensive

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​

  ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income (Loss)

  ​ ​ ​

Total

​

 

  ​

 

​

  ​

 

  ​

 

​

  ​

 

  ​

 

​

  ​

​

 

  ​

  ​ ​ ​

​

  ​

  ​ ​ ​

​

  ​

​

​

  ​

​

​

 

​

​

  ​

Balance July 1, 2025

 

223

​

$

267,761

​

5,500

​

$

446,942

​

—

​

$

—

​

​

2,504,911

​

$

251

​

$

81,747,969

​

$

(64,504,257)

​

$

5,702

​

$

17,249,665

​

 

​

​

 

  ​

​

​

​

 

  ​

​

​

​

 

  ​

​

​

​

​

 

  ​

​

 

​

​

 

​

​

​

​

​

 

​

Stock based compensation

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

—

​

 

—

​

 

53,774

​

 

—

​

​

—

​

 

53,774

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Exercise of investor warrants

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

512,699

​

​

51

​

​

1,530,406

​

​

—

​

​

—

​

​

1,530,457

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of common stock for consulting fees

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

727

​

 

—

​

 

4,500

​

 

—

​

​

—

​

 

4,500

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of warrants for consulting fees

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

—

​

​

1,039,089

​

​

—

​

​

—

​

​

1,039,089

​

 

​

​

 

  ​

​

​

​

 

  ​

​

​

​

 

  ​

​

​

​

​

 

  ​

​

 

​

​

 

​

​

​

​

​

 

​

Preferred stock dividends

​

—

​

​

—

​

—

​

​

45,210

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

(45,210)

​

​

—

​

​

(45,210)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock redemptions and conversions

​

(223)

​

​

(267,761)

​

(4,296)

​

​

(1,078,832)

​

—

​

​

—

​

​

1,509,075

​

​

151

​

​

1,346,442

​

​

—

​

​

—

​

​

1,346,593

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock accretion

​

—

​

​

—

​

—

​

​

1,190,477

​

—

​

​

—

​

​

—

​

​

—

​

​

(1,190,477)

​

​

—

​

​

—

​

​

(1,190,477)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net loss

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

—

​

 

—

​

 

—

​

 

(3,923,247)

​

​

—

​

 

(3,923,247)

​

 

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Balance September 30, 2025

​

—

​

$

—

​

1,204

​

$

603,797

​

—

​

$

—

​

​

4,527,412

​

$

453

​

$

84,531,703

​

$

(68,472,714)

​

$

5,702

​

$

16,065,144

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three Months Ended September 30, 2026

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Additional

​

​

​

Accumulated Other

​

​

​

​

​

Series C Preferred Stock

​

Series D Preferred Stock

​

Series E Preferred Stock

​

​

Common Stock

​

Paid-In

​

Accumulated

​

Comprehensive

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​

  ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income (Loss)

  ​ ​ ​

Total

​

  ​ ​ ​

  ​

  ​ ​ ​

​

  ​

  ​ ​ ​

  ​

  ​ ​ ​

​

  ​

  ​ ​ ​

  ​

  ​ ​ ​

​

  ​

  ​

  ​

  ​

  ​ ​ ​

​

  ​

  ​ ​ ​

​

  ​

  ​ ​ ​

​

  ​

  ​ ​ ​

​

 

  ​ ​ ​

​

  ​

Balance July 1, 2026

 

—

​

$

—

​

679

​

$

686,026

​

11,000

​

$

3,858,655

​

​

7,473,112

​

$

748

​

$

94,388,864

​

$

(81,645,998)

​

$

5,702

​

$

12,749,316

​

 

​

​

 

​

​

​

​

 

  ​

​

​

​

 

  ​

​

​

​

​

 

  ​

​

 

​

​

 

​

​

​

​

​

 

​

Stock based compensation

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

—

​

​

382,335

​

​

—

​

​

—

​

​

382,335

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of common stock for consulting fees

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

1,123

​

 

—

​

 

4,500

​

 

—

​

​

—

​

 

4,500

​

 

​

​

 

​

​

​

​

 

  ​

​

​

​

 

  ​

​

​

​

​

 

​

​

 

​

​

 

​

​

​

​

​

 

​

Issuance of warrants for consulting fees

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Accrual of preferred stock dividends

​

—

​

​

—

​

—

​

​

8,545

​

—

​

​

316,711

​

​

—

​

​

—

​

​

—

​

​

(325,256)

​

​

—

​

​

(325,256)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Payment of preferred stock dividends

​

—

​

​

—

​

—

​

​

(8,545)

​

—

​

​

(188,378)

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock redemptions and conversions

​

—

​

​

—

​

—

​

​

—

​

(1,947)

​

​

(1,946,752)

​

​

505,650

​

​

51

​

​

1,946,701

​

​

—

​

​

—

​

​

1,946,752

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock accretion

 

—

​

 

—

​

—

​

 

—

​

—

​

 

2,147,299

​

​

—

​

 

—

​

 

(2,147,299)

​

 

—

​

​

—

​

 

(2,147,299)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net income

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

—

​

 

—

​

 

—

​

 

6,458,553

​

​

—

​

 

6,458,553

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Balance September 30, 2026

 

—

​

$

—

​

679

​

$

686,026

​

9,053

​

$

4,187,535

​

​

7,979,885

​

$

799

​

$

94,575,101

​

$

(75,512,701)

​

$

5,702

​

$

19,068,901

​

​

6

Table of Contents

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Nine Months Ended September 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Additional

​

​

​

​

Accumulated Other

​

​

​

​

​

Series C Preferred Stock

​

Series D Preferred Stock

​

Series E Preferred Stock

​

​

Common Stock

​

Paid-In

​

Accumulated

​

Comprehensive

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​

  ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income

  ​ ​ ​

Total

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Balance January 1, 2025

 

4,285

​

$

912,830

​

—

​

$

—

​

—

​

$

—

​

​

1,357,165

​

$

137

​

$

53,027,049

​

$

(47,169,206)

​

$

5,702

​

$

5,863,682

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Stock based compensation

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

73,971

​

 

7

​

 

639,590

​

 

—

​

​

—

​

 

639,597

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Exercise of investor warrants

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

674,707

​

 

67

​

 

2,014,716

​

 

—

​

​

—

​

 

2,014,783

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of common stock for consulting fees

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

35,244

​

​

3

​

​

113,613

​

​

—

​

​

—

​

​

113,616

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of warrants for consulting fees

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

—

​

​

1,763,319

​

​

—

​

​

—

​

​

1,763,319

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of Series D Preferred Stock and warrants

​

—

​

​

—

​

5,500

​

​

105,341

​

—

​

​

—

​

​

—

​

​

—

​

​

157,442

​

​

—

​

​

—

​

​

157,442

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock dividends paid

​

—

​

​

80,363

​

—

​

​

62,016

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

(142,379)

​

​

—

​

​

(142,379)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Deemed dividends on preferred stock

 

—

​

 

106,973

​

—

​

 

—

​

—

​

 

—

​

​

—

​

 

—

​

 

—

​

 

(106,973)

​

​

—

​

 

(106,973)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock redemptions and conversions

​

(4,285)

​

​

(4,851,157)

​

(4,296)

​

​

(1,078,832)

​

—

​

​

—

​

​

2,386,325

​

​

239

​

​

4,294,589

​

​

—

​

​

—

​

​

4,294,828

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock accretion

​

—

​

​

3,407,659

​

—

​

​

1,515,272

​

—

​

​

—

​

​

—

​

​

—

​

​

(4,922,931)

​

​

—

​

​

—

​

​

(4,922,931)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Modification of Series C preferred stock

​

—

​

​

343,332

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

—

​

​

6,017,668

​

​

—

​

​

—

​

​

6,017,668

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Reclassification of warrants upon amendment

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

—

​

​

21,426,648

​

​

—

​

​

—

​

​

21,426,648

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net loss

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

—

​

 

—

​

 

—

​

 

(21,054,156)

​

​

—

​

 

(21,054,156)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Balance September 30, 2025

​

—

​

$

—

​

1,204

​

$

603,797

​

—

​

$

—

​

​

4,527,412

​

$

453

​

$

84,531,703

​

$

(68,472,714)

​

$

5,702

​

$

16,065,144

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Nine Months Ended September 30, 2026

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Additional

​

​

​

​

Accumulated Other

​

​

​

​

​

Series C Preferred Stock

​

Series D Preferred Stock

​

Series E Preferred Stock

​

​

Common Stock

​

Paid-In

​

Accumulated

​

Comprehensive

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​

  ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Income

  ​ ​ ​

Total

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Balance January 1, 2026

 

—

​

$

—

​

679

​

$

507,927

​

11,000

​

$

338,774

​

​

7,448,343

​

$

746

​

$

97,242,028

​

$

(76,196,995)

​

$

5,702

​

$

21,051,481

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Stock based compensation

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

—

​

 

—

​

 

700,660

​

 

—

​

​

—

​

 

700,660

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of common stock for consulting fees

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

25,892

​

​

2

​

​

113,452

​

​

—

​

​

—

​

​

113,454

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Issuance of warrants for consulting fees

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

​

—

​

​

—

​

​

584,487

​

​

—

​

​

—

​

​

584,487

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Accrual of preferred stock dividends

​

—

​

​

—

​

—

​

​

25,635

​

—

​

​

704,050

​

​

—

​

​

—

​

​

—

​

​

(729,685)

​

​

—

​

​

(729,685)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Payment of preferred stock dividends

​

—

​

​

—

​

—

​

​

(32,166)

​

—

​

​

(736,134)

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock redemptions and conversions

​

—

​

​

—

​

—

​

​

—

​

(1,947)

​

​

(1,946,752)

​

​

505,650

​

​

51

​

​

1,946,701

​

​

—

​

​

—

​

​

1,946,752

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred stock accretion

​

—

​

​

—

​

—

​

​

184,630

​

—

​

​

5,827,597

​

​

—

​

​

—

​

​

(6,012,227)

​

​

—

​

​

—

​

​

(6,012,227)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net income

 

—

​

 

—

​

—

​

 

—

​

—

​

 

—

​

​

—

​

 

—

​

 

—

​

 

1,413,979

​

​

—

​

 

1,413,979

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Balance September 30, 2026

​

—

​

$

—

​

679

​

$

686,026

​

9,053

​

$

4,187,535

​

​

7,979,885

​

$

799

​

$

94,575,101

​

$

(75,512,701)

​

$

5,702

​

$

19,068,901

​

See accompanying notes to these Condensed Consolidated financial statements.

​

7

Table of Contents

​

TAO SYNERGIES INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

​

​

​

​

​

​

​

​

  ​ ​ ​

Nine Months Ended

  ​ ​ ​

Nine Months Ended

​

​

September 30, 2026

​

September 30, 2025

CASH FLOW USED IN OPERATING ACTIVITIES

​

​

​

​

​

​

Net income (loss)

​

$

1,413,979

​

$

(21,054,156)

Adjustments to reconcile net income (loss) to net

​

​

​

​

​

​

cash used by operating activities

​

​

​

​

​

​

Stock based compensation

​

​

700,660

​

​

639,590

Accrual of Restricted Stock Awards

​

​

—

​

​

—

Non-cash revenue from digital assets

​

​

(723,124)

​

​

(207,333)

Unrealized (gain) loss on digital assets

​

​

(6,729,488)

​

​

2,396,497

Warrant issuance costs

​

​

—

​

​

699,845

Change in fair value of Yuma partnership investments

​

​

(310,578)

​

​

—

Change in fair value of warrant liability

​

​

1,000

​

​

13,055,585

Change in fair value of derivative liability

​

​

1,125,000

​

​

76,000

Consulting services paid by issuance of common stock

​

​

113,454

​

​

113,616

Consulting services paid by issuance of warrants

​

 

584,487

​

 

418,773

Depreciation expense

​

 

2,286

​

 

2,814

Change in assets and liabilities:

​

​

​

​

​

​

Decrease (increase) in prepaid expenses and other current assets

​

 

1,051,595

​

 

(113,223)

(Decrease) increase in accounts payable

​

 

(197,781)

​

 

632,363

(Decrease) in accrued expenses

​

 

(479,622)

​

 

(604,584)

​

​

 

(4,862,111)

​

 

17,109,943

​

​

​

​

​

​

​

Net Cash Used in Operating Activities

​

 

(3,448,132)

​

 

(3,944,213)

​

​

​

​

​

​

​

CASH FLOWS USED IN INVESTING ACTIVITIES

​

​

​

​

​

​

Purchase of crypto currency

​

​

—

​

​

(17,570,203)

​

​

​

​

​

​

​

Net Cash Used in Investing Activities

​

​

—

​

​

(17,570,203)

​

​

​

​

​

​

​

CASH FLOWS FROM FINANCING ACTIVITIES

​

​

​

​

​

​

Proceeds from investor warrant exercises

​

​

—

​

​

2,014,783

Net proceeds from Series D Convertible Preferred Stock offering

​

​

—

​

​

4,924,000

Redemption of Series C Convertible Preferred Stock

​

​

—

​

​

(1,430,000)

Dividends on Convertible Preferred Stock

​

​

(768,300)

​

​

(205,161)

​

​

​

​

​

​

​

Net Cash (Used in) / Provided by Financing Activities

​

​

(768,300)

​

​

5,303,622

​

​

 

​

​

 

​

NET DECREASE IN CASH AND EQUIVALENTS

​

 

(4,216,432)

​

 

(16,210,794)

​

​

 

​

​

 

​

CASH AND EQUIVALENTS AT BEGINNING OF PERIOD

​

 

5,497,671

​

 

17,656,221

​

​

 

​

​

 

​

CASH AND EQUIVALENTS AT END OF PERIOD

​

$

1,281,239

​

$

1,445,427

​

​

​

​

​

​

​

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

​

​

​

​

​

​

Interest

​

$

—

​

$

—

Income taxes

​

$

—

​

$

—

​

​

​

​

​

​

​

DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

​

​

​

​

​

​

​

​

​

​

​

​

​

Accretion of Series C Convertible Preferred Stock to redemption value

​

$

—

​

$

3,407,659

Accretion of Series D Convertible Preferred Stock to redemption value

​

$

184,630

​

$

1,515,272

Accretion of Series E Convertible Preferred Stock to redemption value

​

$

5,827,597

​

$

—

Warrant liability upon issuance of Series D Convertible Preferred stock

​

$

—

​

$

5,248,062

Reclassification of warrant liability

​

$

—

​

$

21,426,648

Derivative liability upon issuance of Series D Convertible Preferred stock

​

$

—

​

$

113,000

Reclassification of derivative liability

​

$

—

​

$

6,361,000

Series C Convertible Preferred Stock conversions and redemptions

​

$

—

​

$

4,294,589

Issuance of Consultant Warrants

​

$

—

​

$

1,763,319

Deemed dividend on Series E Warrants

​

$

6,229,000

​

$

—

​

See accompanying notes to these Condensed Consolidated financial statements.

8

Table of Contents

​

TAO SYNERGIES INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

Unless the context otherwise indicates, references in these Notes to the accompanying financial statements to “we,” “us,” “our” and “the Company” refer to TAO Synergies Inc. and together with its wholly owned subsidiaries (formerly known as Synaptogenix, Inc. and Neurotrope Bioscience, Inc.), a Delaware corporation. References to “Neurotrope”, “Parent Company” or “Parent” refer to Neurotrope, Inc., a Nevada corporation.

Note 1 – Organization, Business, Risks and Uncertainties:

Organization and Business

On May 17, 2020, Neurotrope, Inc. (“Neurotrope” or “the Parent”) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement between Neurotrope and Synaptogenix (the “Separation and Distribution Agreement”), Neurotrope distributed all of its equity interest in this wholly owned subsidiary to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and the Company operates independently from Neurotrope. On December 7, 2020, the Company became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (“Synaptogenix”) when Synaptogenix filed an amended and restated certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. (the “Company”).

On June 9, 2025, in connection with the Company’s previously announced exploration of strategic opportunities, the Company announced the launch of a differentiated cryptocurrency treasury strategy focused on the pure play artificial intelligence (“AI”) crypto coin, TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI. On June 25, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State for the State of Delaware, effective June 26, 2025, to change the name of the Company from “Synaptogenix, Inc.” to “TAO Synergies Inc.”

On September 26, 2025, the Company formed a subsidiary TAOX Florida Inc. for the purpose of facilitating the Company’s expansion into the cryptocurrency treasury strategy business.

On October 21, 2026, the Company formed a subsidiary AlphaSynergies.ai for the purpose of facilitating the Company’s expansion into the artificial intelligence (“AI”) business leveraging off its existing cryptocurrency treasury strategy.

The Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), are listed on The Nasdaq Capital Market under the symbol “TAOX.”

Background on TAO and Bittensor

Bittensor is a public Layer 1 blockchain, called Subtensor, built with the Substrate framework and organized into independent “subnets” where miners produce digital commodities (commonly AI outputs) and validators evaluate them. Depending on the subnet’s incentive mechanism, miners may produce digital commodities that can include, for example, text prompt completions and other question-answer outputs, vector embeddings and related semantic search or ranking outputs, code-related outputs, image generation outputs, and speech-to-text transcription outputs. On chain, an algorithm named Yuma Consensus aggregates validators’ rankings of miners to compute emissions (new tokens minted by the protocol) for miners, validators, stakers, and subnet creators. This mechanism is widely referred to in project materials as Bittensor’s “Proof-of-Intelligence” consensus model. In this context, “consensus” refers to stake-weighted convergence on subnet validator scoring used to allocate emissions and other incentives, and not to transaction ordering or block finality, which are currently provided on Subtensor through a separate proof-of-authority authority set. Subtensor’s transaction ordering and block finality are currently provided by a proof of authority model under which a small, permissioned “authority set” produces and finalizes blocks. TAO is the Network’s native token and is used to pay transaction fees, incentivize subnet participants, and for staking. Staking TAO affects how emissions and incentives are allocated (including by influencing validator stake weight and related reward calculations and, under dTAO (defined below), by staking into a subnet’s on-chain pool to receive that subnet’s alpha token) and may affect governance participation. Staking TAO does not itself validate or finalize Subtensor transactions. TAO is, however, also used for governance (including voting power that may be exercised directly or via delegation) and may be used to create/register subnets under protocol rules.

9

Table of Contents

​

As of November 13, 2026, TAO’s circulating supply was approximately 11.7 million tokens with a market capitalization of approximately $2.53 billion, according to publicly available sources. The lifecycle of TAO follows a supply schedule. Approximately one block is produced every ~12 seconds, with 1 TAO per block minted before the first halving (about 7,200 TAO/day), and 0.5 TAO per block minted after the first halving (about 3,600 TAO/day). The first halving occurred when total issuance reached 10.5 million TAO on December 15, 2025. TAO is not halved on a daily basis. Instead, the per-block emission rate decreases by 50% when predetermined issuance thresholds are reached. TAO has a hard cap of 21,000,000 tokens. Subtensor transaction fees are paid in TAO. Current public documentation indicates that transaction fees are deducted from total issuance rather than distributed as rewards. Accordingly, subnet miners and subnet validators generally do not receive TAO as transaction-fee awards for validating transactions, and instead earn rewards primarily through protocol emissions. In addition, per current documentation, certain staking-related transactions are described as subject to a percentage-based fee (for example, 0.05% of the TAO amount being staked or unstaked), in addition to any weight-based transaction fees (in this context “weight” is a measure of compute time).

Under the February 13, 2025 Dynamic TAO (“dTAO”) upgrade, newly issued TAO is first routed to subnets under protocol rules that, as of November 2025, allocate TAO across subnets based on net TAO inflows from staking activity rather than subnet token prices, and staking into a subnet exchanges TAO for that subnet’s alpha token. Subnet alpha tokens are subnet-specific tokens a participant receives when staking TAO into the subnet’s on-chain market pool, and the alpha token to subnet exchange rate is generally determined by the pool’s reserves. Exits convert alpha tokens back to TAO at the prevailing pool exchange rate at the time of conversion, so outcomes are price sensitive. According to current documentation, emissions for each subnet are generally distributed at the end of every approximately 360 blocks, or about 72 minutes, and the subnet’s participant distribution is generally allocated 41% to miners, 41% to validators and their stakers, and 18% to the subnet owner. The Bittensor blockchain does not impose protocol-enforced delays (unbonding periods) in accessing unstaked TAO. That said, custodians, validators, liquidity pools, or other service providers and operational setups may impose operational, contractual, or practical limits on withdrawal timing or liquidity.

The initial Bittensor mainnet “Kusanagi” launched in January 2021, was followed by the “Nakamoto” upgrade in November 2021, then a fork to the current “Finney” chain on March 20, 2023. Subnets went live on October 2, 2023. Governance has transitioned to a bicameral model in which a “Triumvirate” (employees of the Opentensor Foundation) authors proposals and a “Senate” (a group of delegates who have elected to participate in proposals) must approve the proposals prior to implementation. The Senate is comprised of the top delegate hotkeys by stake. In this specific context, a “hotkey” is the operational public key used by a participant to conduct on-chain actions (including by a validator), and a “delegate” is a hotkey that accepts delegated TAO from third parties for staking. “Top” refers to the delegate hotkeys with the highest total stake at a given time. Per current documentation, the Senate has 12 seats (although not all must be filled), and a delegate generally must reach at least 2% of total network stake amount through delegation or self-stake and elect to participate in the Senate. If all twelve Senate seats are filled, and a delegate wishes to join, the lowest stake member is replaced. Because Senate membership is stake-based, governance influence may be concentrated among large stakers and delegates.

Our Cryptocurrency Asset Strategy

In June 2025, the Company adopted a differentiated cryptocurrency treasury strategy focused on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor. Bittensor is a decentralized blockchain network for machine learning and AI. This was a shift from our prior approach of holding excess cash (as defined below) primarily in Federal Deposit Insurance Corporation (“FDIC”)-insured interest-bearing accounts. We now seek to allocate substantial portions of our excess cash to purchasing TAO, with the goal of obtaining an increased yield on excess cash by staking TAO for revenue generation and capital appreciation, a strategy that underscores our mission to create significant value for shareholders.

To identify “excess cash,” the Company first evaluates its cash, cash equivalents, and short-term investments (collectively, “cash assets”). The Company then estimates the amount of cash assets required to fund approximately 1.5 to 2.0 years of projected operating and working capital needs. Cash assets in excess of this estimated liquidity requirement are considered “excess cash” for purposes of its TAO accumulation strategy. By allocating a substantial portion of its excess cash to TAO, the Company generally means that we seek to allocate between 75 percent and 100 percent of this excess cash to the purchase of TAO. However, actual allocation levels may vary due to market conditions, the prevailing price of TAO, liquidity needs, and other factors considered by management.

10

Table of Contents

​

To guide its cryptocurrency asset purchases, the Company’s Board of Directors (the “Board”) adopted a long-only TAO accumulation strategy and has delegated authority to our Executive Chairman, in consultation with internal personnel and external advisors, to determine the timing, size, and method of TAO purchases with the objective of maximizing tokens per share. Under this authority, management reviews our cash assets, identifies any excess cash as described above, and determines whether to allocate such excess cash to the acquisition of TAO. In addition to using excess cash, the Company’s acquisition strategy may also involve issuing debt or equity securities or undertaking other capital raising transactions, subject to market conditions, with the objective of using the proceeds to purchase additional TAO.

The Company has not established a specific target amount of TAO that we seek to hold. Instead, the Company monitors market conditions, liquidity needs, and financing opportunities in determining whether to make additional TAO purchases in the future. The Company views its TAO holdings as long-term holdings and expects to continue accumulating TAO over time. As of September 30, 2026, approximately 95.2% of the Company’s treasury holdings were invested in TAO. The Company does not hedge our TAO exposure and has no diversification strategy into other crypto assets. Accordingly, the Company’s treasury strategy currently reflects long-only exposure to TAO. However, the Company is exploring the potential implementation of hedging strategies to manage risks associated with digital asset price volatility; the Company has not implemented any hedging strategies to date, and there can be no assurance that any such strategies will be implemented or, if implemented, effective.

Although a liquid market for TAO exists, the Company has not monetized (i.e., sold) any TAO to date. A majority of the Company’s TAO is staked as soon as trade settlement permits, and the Company currently stakes TAO through one staking provider Yuma Validator, LLC (“Yuma”). The Company only engages in TAO staking. In the future, the Company may explore additional yield-enhancement strategies, including participation in Bittensor subnets. Any such activity would likely be undertaken with a third-party partner possessing substantial subnet expertise.

Liquidity Uncertainties

As of September 30, 2026, the Company had approximately $1.3 million in cash and cash equivalents and approximately $25.4 million in digital asset value as compared to $23.4 million of cash, cash equivalents and digital asset value at December 31, 2025. The Company expects that its current cash and cash equivalents and TAO token market value, approximately $16.7 million as of the date of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next 12 months from the date of this Quarterly Report. The Company’s ability to meet these requirements depends in part on its ability to sell TAO, which it has not done to date, at prices that may be significantly lower than current market prices. The operating requirements include the current plans for increasing its TAO holdings and staking while determining its strategy for Bryostatin-1, the Company’s novel drug candidate targeting the activation of Protein Kinase C Epsilon (PKC ε). The financial commitments include the potential redemption of the remaining Series D convertible preferred stock, par value $0.0001 per share, with a stated value of $1,000 per share (the “Series D Convertible Preferred Stock”) and the potential redemption of the remaining Series E convertible preferred stock, par value $0.0001 per share, with a stated value of $1,000 per share (the “Series E Convertible Preferred Stock”), for cash.

The Company expects to need additional capital in order to continue pursuing its TAO treasury and AI strategies. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on its business, financial condition and results of operations.

Other Risks and Uncertainties

The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological and regulatory. Such factors include, but are not necessarily limited to, market conditions of, and overall sentiment towards, the cryptoeconomy, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with the Company’s Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”) licensing agreement, and the ability to raise capital to achieve strategic objectives. The Company maintains its digital assets with a third-party custodian. As a result, the Company is exposed to custodial concentration risk related to the safekeeping and access to such assets. See additional risks and uncertainties set forth under the heading “Risk Factors” contained elsewhere in this Quarterly Report on Form 10-Q.

11

Table of Contents

​

Note 2 – Summary of Significant Accounting Policies:

Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company’s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2026 may not be indicative of results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes to those statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2026.

Use of Estimates:

The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results.

Comprehensive Income (Loss)

The Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 220 in reporting comprehensive income (loss). Comprehensive income (loss) is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income (loss). For the three and nine months ended September 30, 2025, the Company had no items of other comprehensive income (loss); accordingly, comprehensive income (loss) equals net income (loss).

Net Earnings per Share

The Company computes earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings per share for Common Stock and any participating securities according to dividends declared (whether paid or unpaid) and participation rights in undistributed earnings. The Series D and Series E Preferred Shares are considered participating securities as preferred shareholders are entitled to participate with common stockholders on an as-converted basis in any distributions of assets by the Company under the terms of the Certificate of Designations.

12

Table of Contents

​

The following table illustrates the computation of basic and diluted earnings per share for the three months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Net income (loss)

​

$

6,458,553

​

$

(3,923,247)

Less: Convertible preferred stock dividends

​

 

(325,256)

​

 

(45,210)

Less: deemed dividend on Series E warrant repricing

​

 

(2,071,000)

​

 

—

Less: allocation of undistributed income to Series D convertible preferred stockholders

​

 

(88,438)

​

 

—

Less: allocation of undistributed income to Series E convertible preferred stockholders

​

 

(1,083,233)

​

 

—

​

​

​

​

​

​

​

Net income (loss) available to common stockholders – basic

​

$

2,890,626

​

$

(3,968,457)

Effect of dilutive instrument on net income

​

 

1,000

​

 

—

Net income (loss) available to common stockholders - diluted

​

$

2,891,626

​

$

(3,968,457)

​

​

​

​

​

​

​

Weighted average shares outstanding - basic

​

 

7,538,500

​

 

2,549,600

​

​

​

​

​

​

​

Dilutive effect of warrants and options

​

 

51,553

​

 

—

​

​

​

​

​

​

​

Weighted average shares outstanding - diluted

​

 

7,590,053

​

 

2,549,600

​

​

​

​

​

​

​

Basic earnings per share

​

$

0.38

​

$

(1.56)

Diluted earnings per share

​

$

0.38

​

$

(1.56)

​

The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive as determined using the treasury stock method (for the Common Stock Options and Common Stock Warrants) or if-converted method (for the Convertible Preferred Stock) for the three months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

For the Three Months Ended

​

  ​ ​ ​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Common Stock Options

 

431,081

​

79,186

Convertible Preferred Stock

​

—

​

1,209,051

Common Stock Warrants

 

4,708,288

​

4,696,939

Total

 

5,139,369

​

5,985,176

​

13

Table of Contents

​

The following table illustrates the computation of basic and diluted earnings per share for the nine months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Net income (loss)

​

$

1,413,979

​

$

(21,054,156)

Less: Convertible preferred stock dividends

​

 

(729,685)

​

 

(249,352)

Less: deemed dividend on Series E warrant repricing

​

 

(6,229,000)

​

 

—

​

​

​

​

​

​

​

Net income (loss) available to common stockholders - basic

​

$

(5,544,706)

​

$

(21,303,508)

Net income (loss) available to common stockholders - diluted

​

$

(5,544,706)

​

$

(21,303,508)

​

​

​

​

​

​

​

Weighted average shares outstanding - basic

​

 

7,493,400

​

 

2,164,500

​

​

​

​

​

​

​

Dilutive effect of warrants and options

​

 

—

​

 

—

​

​

​

​

​

​

​

Weighted average shares outstanding - diluted

​

 

7,493,400

​

 

2,164,500

​

​

​

​

​

​

​

Basic earnings per share

​

$

(0.74)

​

$

(9.84)

Diluted earnings per share

​

$

(0.74)

​

$

(9.84)

​

The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive as determined using the treasury stock method (for the Common Stock Options and Common Stock Warrants) or if-converted method (for the Convertible Preferred Stock) for the nine months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

For the Nine Months Ended

​

​

September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Common Stock Options

 

260,888

 

49,153

Convertible Preferred Stock

 

3,061,617

 

1,255,771

Common Stock Warrants

 

3,867,010

 

2,907,340

Total

 

7,189,515

 

4,212,264

​

Cash and Cash Equivalents and Concentration of Credit Risk:

The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2026, the Company’s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (“FDIC”) were $0. In addition, approximately $1.3 million included in cash and cash equivalents were invested in a money market fund and in U.S. treasury bills, and approximately $25.4 million in cryptocurrency, at market value, which is not insured under the FDIC.

Investment in Limited Partnership Interests

As permitted under ASC Topic 825 - Financial Instruments (“ASC 825”), the Company has elected the fair value option for its investment in limited partnership interests which otherwise would be subject to ASC Topic 323 - Investment - Equity Method and Joint Ventures. Pursuant to ASC Topic 820 - Fair Value Measurement, because the investments do not have a readily determinable fair value the Company has elected to use net asset value per share or its equivalent (“NAV”) as a practical expedient to measure the Company’s investment at fair value, unless it is probable that the investment will be sold at a value different from its NAV, so long as the investee entity calculates NAV in a manner consistent with the measurement principles established by ASC Topic 946, Financial Services—Investment Companies. The Company uses the practical expedient and, accordingly, measures its investments at fair value each reporting period based on the NAV reported by the investee entities.

14

Table of Contents

​

Digital Assets

Effective January 1, 2025, the Company adopted FASB Accounting Standards Update (“ASU”) 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. Under this guidance, crypto assets within the scope of the ASU are measured at fair value each reporting period, with changes in fair value recognized in net income as unrealized gains or losses on digital assets. The Company’s digital assets, which consist solely of $TAO tokens, meet the scope criteria of ASC 350-60. TAO tokens received as staking rewards are initially recognized as noncash consideration under ASC 606 and subsequently measured at fair value under ASC 350-60.

Segments

The Company currently operates in one segment. The Company has included digital asset operations in its non-segmented corporate activities. See Note 10 - Segment Reporting for further discussion.

Fair Value of Financial Instruments:

The carrying amounts reflected in the balance sheets for prepaid expenses and payables approximate fair value due to the short maturities of these instruments. The carrying amounts for warrant liability and derivative liability approximate fair value based on level 3 of the fair value hierarchy. The carrying amounts for digital assets approximate fair value based on level 1 of the fair value hierarchy.

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable markets.

Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

BitGo, Inc. (“BitGo”) secures the Company’s digital assets in regulated, insured, cold storage with BitGo Bank and Trust, N.A. (formerly known as BitGo Trust Company, Inc.) (“BitGo Trust”) and facilitates the Company’s acquisitions of TAO through its affiliated platforms. BitGo serves as the principal market for the Company’s digital assets, and the fair value of digital assets is primarily determined based on pricing data obtained from BitGo. BitGo is a regulated trust company that provides custody, staking, and trading services for institutional clients and maintains insurance coverage for assets held in cold storage. Management selected BitGo based on its regulatory status, security controls, insurance coverage, and experience providing digital asset solutions to institutional clients.

Accounting for Digital Assets

Fair Market Value

Digital assets are measured at their fair market values using the last close price of the day in the Coordinated Universal Time (UTC) time zone at each reporting period end on the balance sheet. The Company’s digital assets are presented as current assets. The majority of the Company’s digital assets are staked with no lock-up period, and are considered current assets in accordance with ASC 210-10-20, Balance Sheet, due to the Company’s ability to sell them in a liquid marketplace and with a reasonable expectation that they will be realized in cash during the normal operating cycle of our business to support operations if needed.

15

Table of Contents

​

Cost Basis

The cost basis of the Company’s digital assets is measured at fair value based on the spot price at the time of receipt, consistent with the applicable guidance under ASC 350-60. The Company has elected to adopt the First-In, First-Out (FIFO) method for determining the cost basis of digital assets disposed of. The method assumes that the assets that were acquired first are disposed of first. Realized gains and losses from the disposal of digital assets are included in other income in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The Company had no realized gains or losses from the disposal of digital assets for the three and nine months ended September 30, 2026 and 2025.

Revenue Recognition - Digital Assets

The Company engages in network-based smart contracts by staking (or delegating) its digital assets with third party validator nodes. Through these contracts, the Company provides digital assets to stake on a node for the purpose of validating transactions and adding blocks to a respective blockchain network. The term of a smart contract can vary based on the rules of the blockchain and the root subnet. Under the applicable protocol, ordinary staking positions may generally be un-staked at any time without an un-bonding period and un-staking settles immediately. The Company only engages in Root staking, in which case the staked position remains denominated in TAO. The Company stakes its TAO directly from qualified custody with BitGo Trust, enabling a yield generation while maintaining the highest standards of security and regulatory compliance. As of September 30, 2026, the Company’s staked assets have immediate terms, meaning there is no lock-up period upon the asset being claimed and un-staked.

​

In exchange for staking the crypto assets on the blockchain, the Company is entitled to a fractional share of the fixed digital asset award a third-party validator node receives for successfully validating or adding a block to the blockchain. This award is remitted in the native token of the validator node and is referred to as a staking reward. The Company’s staking reward received from delegating to a third-party validator node is proportionate to the digital assets staked by the Company compared to the total digital assets staked by all delegators to that node at that time. Token rewards earned from staking are calculated and distributed directly to the Company’s digital wallets by the blockchain networks as part of their consensus mechanisms.

The Company considers the provision of staking services to be an output of the Company’s ordinary activities and accounts for staking rewards under ASC 606. Each provision of delegated staking rights for each assigned validation activity under a smart contract with a network represents a performance obligation. The satisfaction of the performance obligation occurs at a point in time when confirmation is received from the network indicating that the validation is complete and the awards are determined and credited or made available for transfer to the Company. At that point, the fair value of the staking reward is recognized and recorded as revenue. Staking rewards are non-cash consideration and are measured at fair value at the time the staking reward revenue is recognized, using quoted market prices of the underlying digital asset. As a delegator, the Company has concluded that it is not the principal to the block validation service provided to the blockchain as it is the validators that control the service. Instead, the Company’s service is one of providing the use of its assets by the validators to increase their validation opportunities. Consequently, the Company records staking revenue on a net basis, reflecting only the portion of the protocol rewards to which it is entitled after validator fees and commissions have been paid to the validators and custodians. Once the reward has been acquired by the Company, the tokens are added to the Company’s digital asset holdings and their fair value is accounted for in accordance with ASC 820.

Fixed Assets and Leases:

The Company has one lease which has a remaining term of approximately nine months as of September 30, 2026. The Company has deemed the lease immaterial and has not recorded it as an obligation on the balance sheet nor a right-of-use asset. The total remaining future expense relating to this lease is approximately $54,000.

Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between three and ten years.

Research and Development Costs:

All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2026 and December 31, 2025.

16

Table of Contents

​

Income Taxes:

There is no income tax benefit for the income or losses for the three and nine months ended September 30, 2026 and 2025 since management has determined certain US GAAP income recognized items are not currently subject to income taxes, but rather are deferred until a future event.

The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of January 1, 2026, the Company had no unrecognized tax benefits, or any tax related interest or penalties, and it does not expect significant changes in the amount of unrecognized tax benefits to occur within the next twelve months. There were no changes in the Company’s unrecognized tax benefits during the nine month period ended September 30, 2026. The Company did not recognize any interest or penalties during 2026 related to unrecognized tax benefits.

With few exceptions, the U.S. and state income tax returns filed for the tax years ending on December 31, 2022 and thereafter are subject to examination by the relevant taxing authorities. Net operating loss (“NOL”) carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by the statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized.

Recently Issued Accounting Pronouncements:

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220), which requires disclosure in the notes to financial statements about specific types of expenses included in the expense captions presented on the face of the statement of operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact related to the adoption of ASU 2024-03 on its consolidated financial statement disclosures.

Other recently issued accounting pronouncements are not expected to have a material impact on the Company’s condensed consolidated financial statements.

Note 3 – Collaborative Agreements and Commitments:

Strategic Investments in TAO Digital Assets

On June 24, 2025, the Company announced its initial purchase of TAO as part of the Company’s cryptocurrency treasury strategy and that BitGo had been selected to provide qualified custody, staking and trading services for the Company’s TAO holdings.

BitGo secures the Company’s digital assets in regulated, insured cold storage with BitGo Trust and facilitates the Company’s acquisitions of TAO through its affiliated trading platforms, including access to liquidity via its OTC desk. TAO is staked directly from qualified custody with BitGo Trust, enabling the Company to generate staking rewards while the underlying TAO remains in qualified custody. The Company has begun to generate revenue through TAO staking. The initial acquisition of TAO was funded by the Company’s cash reserves.

The Company stakes its TAO holdings and, as a result, earns staking rewards in the form of additional TAO tokens. The Company accounts for its staking rewards under ASC 606. The Company’s performance obligation is to provide delegated staking rights to the third-party validator and is satisfied when those rights are provided. The staking rewards represent variable consideration that is fully constrained until the validator completes the related validation activity, the protocol determines the reward, the applicable validator fees and commissions are determinable, and the net reward is credited or otherwise made available to the Company. At that time, the variable-consideration constraint is resolved, and the Company recognizes staking revenue equal to the fair value of the net TAO reward.

The Company is not the principal for the blockchain validation service because the third-party validator operates the validator node and controls the validation service provided to the blockchain network. Accordingly, the Company recognizes only the portion of the protocol reward to which it is entitled after validator fees and commissions. Separately charged BitGo custody and bring-your-own-validator service fees are recognized as expenses and do not reduce staking revenue.

17

Table of Contents

​

TAO tokens received through staking represent noncash consideration for staking revenue and, therefore, do not themselves result in a cash flow.

The Company’s TAO holdings meet the scope criteria of ASC 350-60, Intangibles—Goodwill and Other—Crypto Assets. Digital assets within the scope of ASC 350-60 are measured at fair value each reporting period. Accordingly, the Company’s purchased TAO and TAO received as staking rewards, following initial recognition under ASC 606, are measured at fair value each reporting period, with changes in fair value recognized in net income. The Company classifies its TAO holdings as current assets because management intends and has the ability to convert the holdings to cash within one year, and the holdings are not subject to a lock-up or other restriction that would prevent such conversion. Fair value is determined using the quoted market price of TAO as of the applicable measurement date and time, applied consistently each reporting period.

TAO tokens are divisible into partial tokens and are presented rounded to the nearest one-hundredth of a token. The following table summarizes the Company’s digital asset holdings as of September 30, 2026:

​

​

​

​

​

​

​

​

​

​

​

​

Assets

  ​ ​ ​

Tokens

  ​ ​ ​

​

Average Cost Basis

  ​ ​ ​

​

Fair Market Value

  ​ ​ ​

​

Cumulative Unrealized Loss

Staked TAO

 

72,193

​

$

24,946,872

​

$

21,707,712

​

$

3,239,160

Un-staked TAO

 

12,212

​

 

4,220,021

​

 

3,672,083

​

 

547,938

Totals

 

84,405

​

$

29,166,893

​

$

25,379,795

​

$

3,787,098

​

Below is a rollforward of digital asset activity for the nine months ended September 30, 2026:

​

​

​

​

​

Balance of Digital Assets as of January 1, 2026

  ​ ​ ​

$

17,927,183

Purchase of TAO tokens

​

​

—

Staking rewards (non-cash additions)

​

​

723,124

Unrealized gain on digital assets

​

​

6,729,488

Balance of Digital Assets as of September 30, 2026

​

$

25,379,795

​

The above rollforward reflects activity in the Company’s TAO holdings, including staking rewards earned, and unrealized changes in fair value during the period, which reconcile to the ending balance. The fair value of TAO is determined using an unadjusted quoted price in an active market for identical TAO tokens and is classified as Level 1 within the fair value hierarchy.

The following table identifies the digital assets earned from staking activities:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

For the Three and Nine Months Ended

​

For the Three and Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2025

Asset

  ​ ​ ​

Token Rewards

​

Revenue

​

Token Rewards

​

 

Revenue

TAO - Nine Months

​

4,442.47

​

$

723,124

​

678.89

​

$

207,333

TAO - Three Months

 

1,097.62

​

$

245,724

​

667.05

​

$

203,371

​

Staking rewards are recognized as revenue, and subsequent changes in the fair value of the Company’s TAO holdings are recognized separately in earnings in the statement of operations.

​

Cost of Revenue

The Company’s cost of revenues related to its digital asset staking are primarily advisory fees incurred for the processing of the staking transactions and fees for BitGo (our cryptocurrency exchange). These costs are directly related to the production of digital asset staking revenues. For the three and nine months ended September 30, 2026, the cost associated with the revenue recorded from digital asset staking was $19,261 and $58,695, respectively.

As of November 16, 2026, the Company had a total of approximately 84,855 TAO tokens with a total market value of approximately $15.8 million, based on quoted market prices at that date.

18

Table of Contents

​

Strategic Investments in Limited Partnership Interests in Yuma

On October 24, 2025, the Company entered into Subscription Agreements (the “Subscription Agreements”) with Yuma Subnet Composite Onshore Fund, L.P. (“YSCO”) and Yuma Large Cap Subnet Onshore Fund, L.P. (“YLCSO”), pursuant to which the Company agreed to purchase from YSCO a 29,794.9626 share interest at a price of $12.59 per share, representing 7.5% of YSCO’s issued and outstanding share capital and agreed to purchase from YLCSO a 32,425.1615 share interest at a price of $11.57 per share, representing 7.5% of YLCSO’s issued and outstanding share capital. Pursuant to the terms of the Subscription Agreements, the Company funded these investments through contributions of TAO, a digital asset, which was measured at fair value on the date of contribution. YSCO and YLCSO were formed to utilize demand for borrowing of TAO tokens by decentralized AI developers by lending TAO tokens and earning a fee for doing so.

The Company evaluated its interests in YSCO and YLCSO under ASC 810, Consolidation, and determined that both entities are variable interest entities (“VIEs”). Under the governing agreements, investment manager has the power to direct the funds’ investment and asset-management decisions, which are the activities that most significantly impact their economic performance. The Company does not have substantive rights to direct those activities. Based on its analysis, the Company concluded that it does not have the power to direct the activities that most significantly impact the economic performance of the VIEs and therefore is not the primary beneficiary. Accordingly, the Company does not consolidate these entities.

The Company has elected the fair value option under ASC 825, Financial Instruments, for these investments at initial recognition. The Company elected the fair value option because it more accurately reflects the value of the investments. Subsequent changes in fair value are recognized in earnings in the period of change.

The Company measures the fair value of its limited partnership interests using the NAV per share (or its equivalent) as a practical expedient in accordance with ASC 820, Fair Value Measurement. Accordingly, these investments are not classified within the fair value hierarchy.

The carrying values are included in Yuma partnership investments on the balance sheets and represent the Company’s maximum exposure to loss. The Company has not provided financial or other support to these VIEs and has no obligation to provide additional funding.

The Company may request to redeem its units in the funds on the last day of each calendar quarter after the units have been outstanding for at least 12 months. Such requests are subject to approval by the funds. Due to this restriction, the Company’s units were not redeemable as of September 30, 2026. The investments will be eligible for redemption beginning on December 31, 2026.

Below is a summary of activity for the Yuma investments as of September 30, 2026:

​

​

​

​

​

Balance of Limited Partnership Interests as of January 1, 2026

  ​ ​ ​

$

446,954

Change in fair value of limited partnership investments

​

​

310,578

Balance as of September 30, 2026

​

$

757,532

​

Stanford License Agreements

On May 12, 2014, the Company entered into a license agreement (the “Stanford License Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. The Company is required to use commercially reasonable efforts to develop, manufacture and sell products (“Licensed Products”) in the Licensed Field of Use (as defined in the Stanford License Agreement) during the term of the licensing agreement which expires upon the termination of the last valid claim of any licensed patent under this agreement. In addition, the Company must meet specific product development milestones, and upon meeting such milestones, make specific milestone payments to Stanford. The Company must also pay Stanford royalties of 3% of net sales, if any, of Licensed Products (as defined in the Stanford License Agreement) and milestone payments of up to $3.7 million dependent upon stage of product development. As of September 30, 2026, no royalties nor milestone payments have been earned or made.

19

Table of Contents

​

On January 19, 2017, the Company entered into a second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,” or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $70,000 upon executing the license and is obligated to pay an additional $10,000 annually as a license maintenance fee. In addition, based upon certain milestones that include product development and commercialization, the Company will be obligated to pay up to an additional $2.1 million and between 1.5% and 4.5% royalty payments on certain revenues generated by the Company relating to the licensed technology. On November 9, 2021, the Company revised the existing licensing agreement with Stanford. The revisions extended all the required future product development and commercialization milestones. The Company is currently in full compliance with the revised agreement and is moving forward on its commitments. As of September 30, 2026, no royalties nor milestone payments have been earned or made.

The Company has advanced the development of synthetic bryostatin by demonstrating the equivalence of the synthetic to the natural bryostatin product. The estimated cost to initiate and produce sufficient quantities of the synthetic bryostatin drug product is approximately $1.5 million. The Company is evaluating production alternatives at this time in light of its new business strategy.

Mt. Sinai License Agreement

On July 14, 2014, the Company entered into an Exclusive License Agreement (the “Mount Sinai License Agreement”) with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai License Agreement, Mount Sinai granted the Company (a) a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) a non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (PKC ε), which includes Niemann-Pick Disease (the “Mount Sinai Field of Use”). The Mount Sinai License Agreement allows the Company to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an orphan drug designation application covering the Data Package (“Mount Sinai Licensed Products”) in the Mount Sinai Field of Use (as such terms are defined in the Mount Sinai License Agreement).

The Company was required to pay Mt. Sinai milestone payments of $2.0 million upon approval of a new drug application (“NDA”) in the United States and an additional $1.5 million for an NDA approval in the European Union or Japan. In addition, the Company was required to pay Mt. Sinai royalties on net sales of licensed product of 2.0% for up to $250 million of net sales and 3.0% of net sales over $250 million. Since inception, the Company has paid Mt. Sinai approximately $210,000 consisting of licensing fees of $135,000 plus development costs and patent fees of approximately $75,000. As of September 30, 2026, no royalties nor milestone payments have been earned or made.

On February 24, 2026, the Company terminated the Mount Sinai License Agreement, effective 60 days from date of termination. The termination does not relieve the parties from obligations under the Mount Sinai License Agreement that accrued prior to the termination and certain other provisions expressly indicated to survive the termination.

Agreements with BryoLogyx

On June 9, 2020, the Company entered into a supply agreement (the “Supply Agreement”) with BryoLogyx Inc. (“BryoLogyx”), pursuant to which BryoLogyx agreed to serve as the Company’s exclusive supplier of synthetic bryostatin. Pursuant to the terms of the Supply Agreement, the Company placed an initial order and subsequently received one gram of current good manufacturing practice (cGMP) synthetic bryostatin as an active pharmaceutical ingredient to be used in a drug product (“API”). The Company may place additional orders for API beyond the initial order by making a written request to BryoLogyx no later than six months prior to the requested delivery date. The Company’s Phase 2 clinical trial in Alzheimer’s disease concluded by the end of 2024 and its Phase 2 clinical trial in multiple sclerosis was discontinued, and the Company is not currently conducting any clinical trials. The Company is not currently using synthetic bryostatin and will determine whether and when to incorporate the synthetic into any future clinical trial process.

20

Table of Contents

​

In connection with the Supply Agreement, on June 9, 2020, the Company entered into a transfer agreement (the “Transfer Agreement”) with BryoLogyx. Pursuant to the terms of the Transfer Agreement, the Company agreed to assign and transfer to BryoLogyx all of the Company’s right, title and interest in and to that certain Cooperative Research and Development Agreement, dated as of January 29, 2019 (the “CRADA”), by and between the Company and the U.S. Department of Health and Human Services, as represented by the NCI, under which Bryostatin-1’s ability to modulate CD22 in patients with relapsed/refractory CD22+ disease has been evaluated to date. Pursuant to guidance provided by NCI, the CRADA has been cancelled and BryoLogyx has initiated a request for a new CRADA in its name. BryoLogyx will be filing its own investigational new drug application (“IND”) for CD22 with the FDA. As consideration for the transfer of rights to the CRADA, BryoLogyx has agreed to pay to the Company 2% of the gross revenue received in connection with the sale of bryostatin products, up to an aggregate payment amount of $1 million. No such revenues have been earned as of September 30, 2026.

Nemours Agreement

On September 5, 2018, the Company announced a collaboration with Nemours A.I. DuPont Hospital (“Nemours”), a premier U.S. children’s hospital, to initiate a clinical trial in children with Fragile X syndrome, a genetic disorder. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours to initiate a clinical trial using Bryostatin-1, under orphan drug status, to treat Fragile X. The Company intends to provide the Bryostatin-1 and obtain the IND, and Nemours intends to provide the clinical site and attendant support for the trial. The Company and Nemours, jointly, will develop the trial protocol. The Company estimates its total trial and IND cost to be approximately $2.0 million. As of September 30, 2026, the Company has incurred cumulative expenses associated with this agreement of approximately $100,000.

The Company has filed an IND with the FDA. The FDA has placed the development of the IND on clinical hold pending completion of further analytics relating to drug pharmacokinetics and pharmacodynamics. The Company is currently evaluating its plans to advance Fragile X development.

CRE License Agreement

Effective October 31, 2012, the Company executed a Technology License and Services Agreement (the “TLSA”) with CRE, a related party, and NRV II, LLC (“NRV II”), another affiliate of CRE, which was amended by Amendment No. 1 to the TLSA as of August 21, 2013, as amended and restated on February 4, 2015 (the “CRE License Agreement”). Pursuant to the CRE License Agreement, CRE and NRV II provide research services and have granted the Company the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October 31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals. Additionally, the CRE License Agreement specifies that all patents that issue from a certain patent application shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain.

After Neurotrope’s initial Series A stock financing, the CRE License Agreement required the Company to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. There were no such statements of work agreements entered into during the nine months ended September 30, 2026.

In addition, in November, 2018, the Company and CRE entered into a second amendment (the “Second Amendment”) to the TLSA pursuant to which CRE granted certain patent prosecution and maintenance rights to the Company. Under the Second Amendment, the Company will have the sole and exclusive right and the obligation, to apply for, file, prosecute and maintain patents and applications for the intellectual property licensed to the Company, and pay all fees, costs and expenses related to the licensed intellectual property.

​

21

Table of Contents

​

Note 4 – Related Party Transactions:

On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Scientific Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee of the Board (the “Bryostatin Development Committee”), consisting of Mr. William Singer and Mr. Joshua Silverman. Dr. Alkon will serve as director of the Bryostatin Platform Development Program and will work with the Bryostatin Development Committee to find and evaluate opportunities for continued development of the Company’s Bryostatin assets. On June 4, 2025, Dr. Alkon entered into a consulting agreement with the Company (the “Alkon Consulting Agreement”). In connection with his resignation, and pursuant to the Alkon Consulting Agreement, the Company and Dr. Alkon agreed to reduce Dr. Alkon’s base monthly salary to $12,500 per month. See Note 5—Other Commitments—Resignation of Dr. Daniel L. Alkon, M.D. On August 9, 2025, the Board reduced Dr. Alkon’s base monthly salary to $1,500 per month. Effective October 10, 2025, the Company terminated the Alkon Consulting Agreement.

On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Board. In consideration of his new role, Mr. Silverman was paid a salary of $30,000 per month. For the three and nine months ended September 30, 2026, $90,000 and $270,000, respectively, is reflected as part of general and administrative expenses in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). On August 14, 2025, the Company entered into an Executive Compensation Agreement (the “Silverman Compensation Agreement”) with Mr. Silverman, effective as of July 1, 2025, pursuant to which Mr. Silverman serves as the Company’s Executive Chairman.

The Silverman Compensation Agreement provides for an initial three-year term, with automatic one-year renewal periods unless either party provides at least ninety (90) days’ prior written notice of non-renewal. Under the Silverman Compensation Agreement, Mr. Silverman is entitled to an annual base salary of $360,000, subject to annual review and potential increase by the Compensation Committee of the Board (the “Compensation Committee”). Mr. Silverman is eligible to receive an annual performance-based bonus. In addition, Mr. Silverman is entitled to receive annual long-term incentive awards under the Company’s Long Term Incentive Plan with a target annual equity award grant date fair value to equal 300% of Mr. Silverman’s base salary.

In the event of termination without “Cause” or by Mr. Silverman for “Good Reason” (as such terms are defined in the Silverman Compensation Agreement), Mr. Silverman is entitled to receive accrued compensation through the termination date, severance equal to two times the sum of his base salary and target bonus (prorated for the year of termination), payable over 24 months, and accelerated vesting of all unvested equity awards. If such termination occurs within two years following or six months preceding a “Change in Control” (as defined in the Silverman Compensation Agreement), Mr. Silverman is entitled to enhanced severance equal to three times the sum of his base salary and target bonus, payable in a lump sum, and full acceleration of all unvested equity awards.

In the event of Mr. Silverman’s death during the term of the Silverman Compensation Agreement, his estate is entitled to receive accrued compensation, any unpaid bonus amounts, accelerated vesting of all unvested equity awards, and any other benefits due under the Company’s benefit plans. In addition, the death benefit under the Company’s life insurance program, if any, will be paid to his designated beneficiary or estate. If Mr. Silverman’s employment terminates due to disability, he is entitled to accrued compensation, prorated target bonus, and continued salary payments for 24 months, along with accelerated vesting of all unvested equity awards and benefits under the Company’s long-term disability insurance plan, if applicable.

All severance and equity acceleration benefits are subject to Mr. Silverman’s execution and non-revocation of a general release of claims. The Silverman Compensation Agreement also includes provisions regarding confidentiality, non-disparagement, post-employment cooperation, and compliance with Section 409A of the Internal Revenue Code. Compensation under the Silverman Compensation Agreement is subject to the Company’s clawback policies as may be required by applicable law or listing standards.

Note 5 – Other Commitments:

Employment Agreements

On June 8, 2025, Dr. Alan J. Tuchman M.D. resigned as Chief Executive Officer of the Company, effective June 8, 2025. On August 28, 2025, Dr. Tuchman further resigned from his position as a member of the Board and as a member of all committees of the Board on which he served. Dr. Tuchman now serves as the Company’s Chief Medical Officer. In connection with his resignation as Chief Executive Officer, the Company and Dr. Tuchman agreed to reduce Dr. Tuchman’s base monthly salary to $7,500 per month. For the three months ended September 30, 2026 and 2025, the Company paid Dr. Tuchman a base salary of $22,500 and $22,500, respectively. For the nine months ended September 30, 2026 and 2025, the Company paid Dr. Tuchman a base salary of $67,500 and $95,000, respectively.

22

Table of Contents

​

As noted above in Note 4—Related Party Transactions, on August 14, 2025, the Company entered into the Silverman Compensation Agreement with Mr. Silverman, effective as of July 1, 2025, pursuant to which Mr. Silverman serves as the Company’s Executive Chairman. See Note 4—Related Party Transactions for additional information regarding the Silverman Compensation Agreement. For the three months ended September 30, 2026 and 2025, the Company paid Mr. Silverman a salary of $90,000 and $90,000, respectively. For the nine months ended September 30, 2026 and 2025, the Company paid Mr. Silverman base compensation of $270,000 and $270,000, respectively.

Consulting Agreements

Consulting Agreement with James Altucher, Z-List Media, OSS Capital LLC and Joseph Jacks

The Company continues to recognize expense related to consulting agreements entered into in 2025 with James Altucher and Z-List Media, Inc. and with OSS Capital LLC and Joseph Jacks. During the three and nine months ended September 30, 2026, the Company recognized non-cash consulting expense of $398,306 and $1,194,918, respectively and, during the three and nine months ended September 30, 2025 the Company recognized non-cash consulting expense of $398,306 and $418,773, respectively, related to these arrangements. As of September 30, 2026, prepaid consulting expense related to these agreements was $655,481.

Additional information regarding these arrangements was previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Contingencies

Pursuant to the Separation and Distribution Agreement and Tax Matters Agreement between Neurotrope and Synaptogenix (the “Tax Matters Agreement”), Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix’s (now TAO Synergies Inc.) business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix (now TAO Synergies Inc.) responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix (now TAO Synergies Inc.) against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix (now TAO Synergies Inc.) is held liable, Synaptogenix (now TAO Synergies Inc.) may be temporarily required to bear these losses. As of the reporting date, there are no claims relating to the indemnification agreement.

​

Note 6 – Stockholders’ Equity:

The Company’s amended and restated certificate of incorporation authorizes it to issue 150,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”).

The holders of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board from time to time may determine. To date, the Company has not paid dividends on its Common Stock. Holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. The Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of Common Stock after payment of liabilities, accrued dividends and liquidation preferences, if any. Each outstanding share of Common Stock is duly and validly issued, fully paid and non-assessable.

June 2025 Private Placement

During 2025, the Company completed a private placement of Series D Convertible Preferred Stock and related warrants (the “Series D Common Stock Warrants”) and entered into related warrant amendments and registration rights agreements. The resale registration statement covering the applicable underlying shares was declared effective by the SEC on July 17, 2025.

23

Table of Contents

​

As of September 30, 2026, 679 shares of Series D Convertible Preferred Stock remained outstanding, convertible into 226,187 shares of Common Stock. Series D Common Stock Warrants to purchase 349,667 shares of Common Stock also remained outstanding. During the three and nine months ended September 30, 2026, the Company recorded dividends/accretion of $8,545 and $210,265, respectively, related to the Series D Convertible Preferred Stock.

The Company was in compliance with the material terms and covenants of the Series D Convertible Preferred Stock arrangements as of September 30, 2026, and there were no material amendments to these arrangements during the current quarter.

October 2025 Private Placement

In October 2025, the Company issued Series E convertible preferred stock, par value $0.0001, with a stated value of $1,000 per share (the “Series E Convertible Preferred Stock”), and related warrants (the “Series E Common Stock Warrants”) in a private placement transaction previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

As of September 30, 2026, 9,053 shares of Series E Convertible Preferred Stock remained outstanding and were convertible into 2,286,493 shares of Common Stock. Series E Common Stock Warrants to purchase 2,971,433 shares of Common Stock also remained outstanding. During the three and nine months ended September 30, 2026, the Company recognized preferred dividends/accretion of $2,464,010 and $6,531,647, respectively, related to the Series E Convertible Preferred Stock.

The Company was in compliance with the material terms and covenants of the Series E Convertible Preferred Stock arrangements as of September 30, 2026, and, other than the July 2026 Adjustment to the Series E Common Stock Warrants described in Note 8, there were no material amendments to these arrangements during the current quarter.

Series B Common Stock Warrants

Pursuant to a November 17, 2022 private placement, the Company issued to investors warrants and, pursuant to its advisory agreements, the Company issued to its advisor additional warrants with the same terms to purchase 2,323 shares of Common Stock with the same terms (the “Series B Broker Warrants”). The Series B Broker Warrants are within the scope of ASC 718 pursuant to ASC 718-10-20 but are subject to liability classification as they would be required to be classified as liabilities in accordance with ASC 480.

The warrants were determined to be within the scope of ASC 480-10 as they are puttable to the Company at the Holders’ election upon the occurrence of a Fundamental Transaction (as defined in the agreements). As such, the Company recorded the warrants as a liability at fair value with subsequent changes in fair value recognized in earnings.

During the three months ended September 30, 2026 and 2025, the Company recorded a loss of $1,000 and a gain of $106,000, respectively and, during the nine months ended September 30, 2026 and 2025, the Company recorded a loss of $1,000 and $336,000, respectively, related to the change in fair value of the Series B warrant liability which is recorded in other income (expense) on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The fair value of the warrants of $10,000 was estimated at September 30, 2026 utilizing the Black Scholes model using the following weighted average assumptions: dividend yield 0%; remaining term of 1.14 years; equity volatility of 110.0%; and a risk-free interest rate of 4.49%.

Accounting Treatment of September 2024 Private Placement

Series C Preferred Shares

As of December 31, 2025, the Series C convertible preferred stock, par value $0.0001, with a stated value of $1,000 per share (the “Series C Convertible Preferred Stock”), had been fully redeemed, and no shares were outstanding as of September 30, 2026. Accordingly, the Company recorded no accretion, dividends, redemption premiums, or change in fair value of the related embedded derivative liability during the three and nine months ended September 30, 2026.

Series C Common Stock Warrants

The Company’s warrants to purchase Common Stock issued in connection with the Company’s private placement of Series C Convertible Preferred Stock in September 2024 (the “Series C Common Stock Warrants”) were liability-classified prior to their reclassification to equity effective June 30, 2025. As a result, the Series C Common Stock Warrants are no longer remeasured at fair value each reporting period.

24

Table of Contents

​

Accounting Treatment of June 2025 Private Placement

Series D Preferred Shares

The Company determined that the Series D Convertible Preferred Stock contains embedded features requiring bifurcation and liability accounting under ASC 815. The embedded derivative liability is remeasured at fair value each reporting period, with changes in fair value recognized in earnings.

During the three months ended September 30, 2026 and 2025, the Company recorded no gain or loss and a gain of $108,000, respectively and, during the nine months ended September 30, 2026 and 2025, the Company recorded a gain of $1,000 and a loss of $2,000, respectively, related to changes in the fair value of the embedded derivative liability associated with the Series D Convertible Preferred Stock, which is included in other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). As of September 30, 2026, the fair value of the embedded derivative liability was approximately $1,000.

The Series D Common Stock Warrants were reclassified from liabilities to equity during 2025 following amendments to the warrant terms. Accordingly, the Series D Common Stock Warrants are no longer remeasured at fair value each reporting period.

Accounting Treatment of October 2025 Private Placement

Series E Preferred Shares

The Company determined that the Series E Convertible Preferred Stock contains embedded features requiring bifurcation and liability accounting under ASC 815. The embedded derivative liability is remeasured at fair value each reporting period, with changes in fair value recognized in earnings.

During the three months ended September 30, 2026 and 2025, the Company recorded a loss of approximately $470,000 and $0, respectively, and, during the nine months ended September 30, 2026 and 2025, the Company recorded a loss of $1,126,000 and $0, respectively, related to the change in fair value of the embedded derivative liability, which is included in other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). As of September 30, 2026, the fair value of the embedded derivative liability was approximately $3.2 million.

The Series E Common Stock Warrants were classified in equity upon issuance and are not remeasured in subsequent reporting periods.

​

Note 7 – Stock-Based Compensation:

2020 Equity Incentive Plan

Upon completion of the Spin-Off, the Company’s 2020 Equity Incentive Plan (the “2020 Plan”) became effective on December 7, 2020. On December 20, 2023, the Company held its annual meeting of stockholders at which time the Company’s stockholders approved an amendment to the Company’s 2020 Plan to increase the total number of shares of Common Stock authorized for issuance from 55,000 to an aggregate of 175,000 shares. On December 6, 2024, The Company held an annual meeting of stockholders whereby the Company’s stockholders approved an amendment to the Company’s 2020 Plan to increase the total number of shares of Common Stock authorized for issuance from 175,000 to 675,000. On August 6, 2025, the Company held a special meeting of stockholders whereby the Company’s stockholders approved amendments to the Company’s 2020 Plan to: (i) change its name to “TAO Synergies Inc. 2020 Equity Incentive Plan” and; (ii) to increase the total number of shares of Common Stock authorized for issuance from 675,000 to 2,675,000.

The Compensation Committee administers the 2020 Plan and has full power to grant stock options and Common Stock, construe and interpret the 2020 Plan, establish rules and regulations and perform all other acts, including the delegation of administrative responsibilities, as it believes reasonable and proper. The Compensation Committee, in its absolute discretion, may award Common Stock to employees, consultants, and directors of the Company, and such other persons as the Compensation Committee may select, and permit holders of options to exercise such options prior to full vesting.

25

Table of Contents

​

Stock and Option Grants

The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2026:

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

​

  ​ ​ ​

​

  ​ ​ ​

Weighted-

  ​ ​ ​

​

​

​

​

​

​

​

Average

​

Aggregate

​

​

​

​

Weighted-

​

Remaining

​

Intrinsic

​

​

Number

​

Average

​

Contractual

​

Value

​

​

of

​

Exercise

​

Term

​

(in

​

​

Shares

​

Price

​

(Years)

​

thousands)

Options outstanding at January 1, 2026

 

93,681

​

$

50.28

 

8.7

​

$

2.2

Options granted

 

337,400

​

$

4.81

 

9.6

​

 

—

Less options forfeited

 

—

​

$

—

 

—

​

 

—

Less options expired/cancelled

 

—

​

$

—

 

—

​

 

—

Less options exercised

 

—

​

$

—

 

—

​

 

—

Options outstanding at September 30, 2026

 

431,081

​

$

14.69

 

9.3

​

$

3.6

Options exercisable at September 30, 2026

 

93,681

​

$

50.28

 

7.9

​

$

3.6

​

​

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing price of the Common Stock, which was $4.53 per share on September 30, 2026 and $3.68 per share on December 31, 2025.

On April 7, 2026, the Company granted an aggregate of 2,400 stock options to three Board members. The stock options have an exercise price of $5.52 per share, vest on the first anniversary of issuance and have an expiration date of ten years from the date of issuance. The Company used the Black Scholes valuation method to determine the fair value of the options assuming the following: implied volatility of 120.6%, a risk-free interest rate of 3.97% and aggregate fair value of $11,379, which is expensed over the vesting term. On May 18, 2026, the Company granted an aggregate of 335,000 stock options to five Board members and one officer. The stock options have an exercise price of $4.80 per share, vest on the first anniversary of issuance and have an expiration date of ten years from the date of issuance. The Company used the Black Scholes valuation method to determine the fair value of the options assuming the following: implied volatility of 120.2%, a risk-free interest rate of 4.29% and aggregate fair value of approximately $1.39 million, which is expensed over the vesting term.

As of September 30, 2026, the Company had unrecognized stock option expense of approximately $0.87 million and a remaining weighted average period for recognition of 0.63 years.

Director’s Compensation Policy

On March 29, 2023, the Company adopted an amended and restated non-employee director compensation policy (the “Director Compensation Policy”). The Director Compensation Policy provides for the annual automatic grant of nonqualified stock options to purchase up to 800 shares of the Company’s Common Stock to each of the Company’s non-employee directors. Such grants occur annually on the fifth business day after the filing of Company’s Annual Report on Form 10-K, if available under the Plan, and vest on the one-year anniversary from the date of grant, subject to the director’s continued service on the Board on the vesting date. Each newly appointed or elected director will also receive 800 options, and such options shall vest 50% on the grant date, 25% on the first anniversary of the grant date and 25% on the second anniversary of the grant date, subject to the director’s continued service on the Board on each vesting date. On April 7, 2026, the Company issued options to purchase a total of 2,400 shares of Common Stock as noted above.

Restricted Stock Issuances

On January 16, 2026, the Company issued 22,563 shares of restricted stock to a consultant engaged to provide investor relations services with a total fair market value on date of issuance of $100,000, expensed upon issuance. On March 6, 2026, the Company issued 1,025 shares of restricted stock to another consultant engaged to provide investor relations services with a total fair market value on date of issuance of $4,454, expensed upon issuance. On June 8, 2026, the Company issued 1,181 shares of restricted stock to another consultant engaged to provide investor relations services with a total fair market value on date of issuance of $4,500, expensed upon issuance. On September 8, 2026, the Company issued 1,123 shares of restricted stock to another consultant engaged to provide investor relations services with a total fair market value on date of issuance of $4,500, expensed upon issuance.

26

Table of Contents

​

Stock Compensation Expense

The Company currently estimates, beginning at the closing date of the Series B offering, implied volatility factor for all options and warrants based upon the Company’s historical volatility. From November 21, 2022 to June 2025, the Company computed implied volatility based upon a blend of the Parent Company’s and Company’s historical volatility along with the volatility of selected comparable publicly traded companies as, at that time, the Company lacked sufficient historical stock trading activity. It incorporated the historical volatility of the Parent Company as the Parent Company’s historical volatility provides a good estimation of the Company’s volatility since its operations were identical to the Company’s prior to the Spin-Off. Since June 2025, the Company used its own implied volatility coupled with comparable company volatilities to arrive at a reasonable estimate of total volatility.

The Company recorded total expenses relating to the outstanding stock options and restricted stock units of $382,335 and $53,774 for the three months ended September 30, 2026 and 2025, respectively and $700,660 and $639,590 for the nine months ended September 30, 2026 and 2025, respectively. Each of these expenses is classified under general and administrative expenses.

​

Note 8 – Common Stock Warrants:

The table below presents a reconciliation of the Company’s outstanding and exercisable warrants for the nine months ended September 30, 2026:

​

​

​

​

​

  ​ ​ ​

Number

​

​

of warrants

Warrants outstanding January 1, 2026

​

3,301,622

Warrants issued

​

1,616,433

Warrants exercised

 

—

Warrants expired

 

(166,526)

Warrants outstanding September 30, 2026

​

4,751,529

Warrants exercisable September 30, 2026

 

4,751,529

​

On May 18, 2026, the Company issued stock options to certain Company officers and directors with an exercise price of $4.80 per share. As a result, the Company issued, to holders of the Series E Warrants, an additional 953,335 warrants pursuant to the repricing triggered by the options issuance and repriced the Series E Warrants to $4.80 per share (the “May 2026 Adjustment”).

​

As a result of the May 2026 Adjustment, the Company recognized the change in the fair value of the Series E Warrants as a deemed dividend in the amount of approximately $4.2 million during the nine months ended September 30, 2026. The Company valued the deemed dividend in connection with the May 2026 Adjustment as the difference between: (a) the modified fair value of the Series E Warrants in the amount of approximately $9.6 million and (b) the fair value of the Series E Warrants prior to the modification of approximately $5.4 million. The fair value of the Series E Warrants before the effect of the May 2026 Adjustment was estimated utilizing the Black Scholes model using the following key inputs and assumptions: the number of shares issuable upon exercise of the Warrants totaling 1,430,000 shares; the exercise price of $8.00 per share; dividend yield of 0%; remaining term of 4.41 years; equity volatility of 130.0%; and a risk-free interest rate of 4.14%. The fair value of the Series E Warrants after the effect of the May 2026 Adjustment was estimated utilizing the Black Scholes model and the following key inputs and assumptions: the number of shares issuable upon exercise of the Series E Warrants totaling 2,383,335 shares; the exercise price of $4.80 per share; dividend yield of 0%; remaining term of 4.41 years; equity volatility of 130.0%; and a risk-free interest rate of 4.14%.

​

On July 6, 2026, the Company issued warrants to a consultant with an exercise price of $3.85 per share. As a result, the Company issued to holders of the Series E Warrants an additional 588,098 warrants pursuant to the repricing triggered by the warrant issuance and repriced the Series E Warrants to $3.85 per share (the “July 2026 Adjustment”). On November 13, 2026, the Company repriced a number of warrants to purchase Common Stock previously issued to Z-List Media, Inc. to an exercise price of $2.10 per share. As a result, the Company repriced the Series D Warrants to $2.10 per share and repriced the Series E Warrants to $2.10 per share.

​

27

Table of Contents

​

As a result of the July 2026 Adjustment, the Company recognized the change in the fair value of the Series E Warrants as a deemed dividend in the amount of approximately $2.1 million during the three and nine months ended September 30, 2026. The Company valued the deemed dividend in connection with the July 2026 Adjustment as the difference between: (a) the modified fair value of the Series E Warrants in the amount of approximately $9.6 million and (b) the fair value of the Series E Warrants prior to the modification of approximately $7.5 million. The fair value of the Series E Warrants before the effect of the July 2026 Adjustment was estimated utilizing the Black Scholes model using the following key inputs and assumptions: the number of shares issuable upon exercise of the Warrants totaling 2,383,335 shares; the exercise price of $4.80 per share; dividend yield of 0%; remaining term of 4.28 years; equity volatility of 130.0%; and a risk-free interest rate of 4.1%. The fair value of the Series E Warrants after the effect of the July 2026 Adjustment was estimated utilizing the Black Scholes model and the following key inputs and assumptions: the number of shares issuable upon exercise of the Series E Warrants totaling 2,971,433 shares; the exercise price of $3.85 per share; dividend yield of 0%; remaining term of 4.28 years; equity volatility of 130.0%; and a risk-free interest rate of 4.14%.

​

As of September 30, 2026, the weighted average exercise price and the weighted average remaining life of the total warrants were $5.54 per warrant and 3.92 years, respectively. The intrinsic value of the warrants as of September 30, 2026 was approximately $881,000. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing price of the Common Stock, which was $4.53 per share on September 30, 2026.

​

Note 9 - Fair Value on a Recurring Basis:

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated embedded derivatives represent Level 3 measurements. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at September 30, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

Description

  ​ ​ ​

Level

  ​ ​ ​

2026

  ​ ​ ​

2025

Liabilities:

 

  ​

 

​

  ​

 

​

  ​

Warrant liability (Note 6)

 

3

​

$

10,000

​

$

9,000

Derivative liability (Note 6)

 

3

​

$

3,239,000

​

$

2,114,000

​

The following table sets forth a summary of the change in the fair value of the Series B Warrant liability that is measured at fair value on a recurring basis:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

For the Three Months Ended September 30,

​

For the Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Beginning balance

​

$

9,000

​

$

752,000

​

$

9,000

​

$

310,000

Change in fair value

​

 

1,000

​

​

(106,000)

​

​

1,000

​

​

336,000

Ending balance

​

$

10,000

​

$

646,000

​

$

10,000

​

$

646,000

​

The following table sets forth a summary of the change in the fair value of the Series D Convertible Preferred Stock bifurcated embedded derivative liability that is measured at fair value on a recurring basis:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

For the Three Months Ended September 30,

​

For the Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Beginning balance

​

$

1,000

​

$

110,000

​

$

2,000

​

$

0

Change in fair value

​

​

0

​

​

(108,000)

​

​

(1,000)

​

​

2,000

Ending balance

​

$

1,000

​

$

2,000

​

$

1,000

​

$

2,000

​

28

Table of Contents

​

The following table sets forth a summary of the change in the fair value of the Series E Convertible Preferred Stock bifurcated embedded derivative liability that is measured at fair value on a recurring basis:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

For the Three Months Ended September 30,

​

For the Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Beginning balance

​

$

2,768,000

​

$

0

​

$

2,112,000

​

$

0

Change in fair value

​

 

470,000

​

​

0

​

​

1,126,000

​

​

0

Ending balance

​

$

3,238,000

​

$

0

​

$

3,238,000

​

$

0

​

​

Note 10 – Business Segment:

The Company operates in one business segment, which consists of research and development activities related to developing therapeutics for neurodegenerative diseases. This determination is consistent with the financial information regularly provided to the Company’s chief operating decision makers (“CODM”). The Company’s CODM for the research and development business is its Chief Medical Officer, in conjunction with the Executive Chairman of the Board, who reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

The Company’s cryptocurrency treasury strategy is managed by the Executive Chairman of the Board in conjunction with the Company’s Chairman of the Audit Committee of the Board and does not represent a separate business segment.

In addition to the significant expense categories included within net loss presented on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), the following table disaggregates the components of research and development expenses:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

For the Three Months Ended September 30, 

​

For the Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

External clinical development expenses

​

$

20,936

​

$

27,305

​

$

41,640

​

$

137,953

Personnel related and stock-based compensation

​

 

—

​

 

13,279

​

 

9,525

​

 

70,362

Other research and development expenses

​

 

8,878

​

 

13,804

​

 

39,104

​

 

55,444

Total research and development expenses

​

$

29,814

​

$

54,388

​

$

90,269

​

$

263,759

​

​

Note 11 – Subsequent Events

The Company evaluated subsequent events through the date the financial statements were issued. Refer to Notes 1, 3 and 8 disclosures of applicable subsequent events along with the below.

Registration Statement on Form S-3

On October 30, 2026, the Company’s Registration Statement on Form S-3 was declared effective by the SEC. See Note 1 (formation of AlphaSynergies.ai) and Note 3 (TAO holdings as of November 16, 2026).

Amendment to Altucher Consulting Agreement

On June 8, 2025, the Company entered into a consulting services agreement (the “Altucher Consulting Agreement”) with James Altucher and Z-List Media, Inc., an entity wholly owned by Mr. Altucher (together, the “Consultant”), with an initial term of one year. On November 13, 2026, the Company and the Consultant entered into Amendment No. 1 to the Altucher Consulting Agreement (the “Consulting Agreement Amendment”), which extends the term through June 8, 2029, unless earlier terminated in accordance with its terms or by mutual written consent of the parties.

29

Table of Contents

​

In consideration of the extension of the term, the Consulting Agreement Amendment reduces the exercise prices of the warrants previously issued to the Consultant as follows: (i) 400,000 warrants, from $4.00 to $2.10 per share; (ii) 200,000 warrants, from $6.00 to $4.00 per share; (iii) 200,000 warrants, from $8.00 to $6.00 per share; and (iv) 400,000 warrants, from $12.00 to $8.00 per share. All other terms of the warrants, including the number of underlying shares, vesting and forfeiture conditions and expiration dates, are unchanged.

Grant of Stock Awards and Stock Options

On November 13, 2026, the Board of Directors of the Company approved the following grants under the 2020 Plan to officers of the Company: (i) to Joshua N. Silverman, Executive Chairman, 131,250 fully vested shares of Common Stock (the “Stock Awards”) and fully vested non-qualified stock options to purchase 131,250 shares of Common Stock; and (ii) to Robert Weinstein, Chief Financial Officer, fully vested non-qualified stock options to purchase 50,000 shares of Common Stock (together with the options granted to Mr. Silverman, the “Options”). The Options have an exercise price of $2.10 per share.

Grant of Subsidiary Stock Awards

As described in Note 1, on October 21, 2026, the Company formed AlphaSynergies.ai (the “Subsidiary”), a wholly owned Nevada subsidiary. On November 13, 2026, the Board of Directors of the Company, as sole stockholder of the Subsidiary and including its disinterested members, approved the Subsidiary’s grant of fully vested shares of Subsidiary common stock (the “Subsidiary Stock Awards”) for services as follows: Joshua N. Silverman, 75,000 shares; Bruce T. Bernstein, 25,000 shares; Robert Weinstein, 12,500 shares; and James Altucher, consultant, 100,000 shares. Messrs. Silverman, Bernstein and Weinstein are related parties of the Company. As of November 16, 2026, the Subsidiary had 1,212,500 shares of common stock outstanding.

​

30

Table of Contents

​

​

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this report and our Annual Report on Form 10-K for the year ended December 31, 2025.

The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on the unaudited financial statements contained in this report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.

Basis of Presentation

The unaudited financial statements for the nine months ended September 30, 2026 and 2025 include a summary of our significant accounting policies and should be read in conjunction with the discussion below and our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in the financial statements. All such adjustments are of a normal recurring nature.

Overview

TAO Synergies Inc. (formerly known as Synaptogenix, Inc.) was previously a biopharmaceutical company with product candidates in pre-clinical and clinical development. We began operations in October 2012. The Company was principally focused on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The Company was also evaluating Bryostatin-1 for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Neurotrope, our predecessor company, had been a party to a technology license and services agreement with the original Blanchette Rockefeller Neurosciences Institute (which has been known as Cognitive Research Enterprises, Inc. since October 2016), and its affiliate NRV II, LLC, which we collectively refer to herein as “CRE,” pursuant to which we now have an exclusive non-transferable license to certain patents and technologies required to develop our proposed products. We were formed for the primary purpose of commercializing the technologies initially developed by BRNI for therapeutic applications for AD or other cognitive dysfunctions. These technologies have been under development by BRNI since 1999 and, until March 2013, had been financed through funding from a variety of non-investor sources (which include not-for-profit foundations, the NIH, which is part of the U.S. Department of Health and Human Services, and individual philanthropists). From March 2013 forward, development of the licensed technology has been funded principally through us in collaboration with CRE.

On June 9, 2025, in connection with the Company’s previously announced exploration of strategic opportunities, the Company announced the launch of a differentiated cryptocurrency treasury strategy focused on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI. On June 25, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State for the State of Delaware, effective June 26, 2025, to change the name of the Company from “Synaptogenix, Inc.” to “TAO Synergies Inc.” On September 26, 2025, the Company formed a subsidiary TAOX Florida Inc. for the purpose of facilitating the Company’s expansion into the cryptocurrency treasury strategy business. On October 23, 2026, the Company formed a subsidiary AlphaSynergies.ai for the purpose of facilitating the Company’s expansion into the artificial intelligence (“AI”) business leveraging off its existing cryptocurrency treasury strategy business.

31

Table of Contents

​

Recent Developments

Background on TAO and Bittensor

Bittensor is a public Layer 1 blockchain, called Subtensor, built with the Substrate framework and organized into independent “subnets” where miners produce digital commodities (commonly AI outputs) and validators evaluate them. Depending on the subnet’s incentive mechanism, miners may produce digital commodities that can include, for example, text prompt completions and other question-answer outputs, vector embeddings and related semantic search or ranking outputs, code-related outputs, image generation outputs, and speech-to-text transcription outputs. On chain, an algorithm named Yuma Consensus aggregates validators’ rankings of miners to compute emissions (new tokens minted by the protocol) for miners, validators, stakers, and subnet creators. This mechanism is widely referred to in project materials as Bittensor’s “Proof-of-Intelligence” consensus model. In this context, “consensus” refers to stake-weighted convergence on subnet validator scoring used to allocate emissions and other incentives, and not to transaction ordering or block finality, which are currently provided on Subtensor through a separate proof-of-authority authority set. Subtensor’s transaction ordering and block finality are currently provided by a proof of authority model under which a small, permissioned “authority set” produces and finalizes blocks. TAO is the Network’s native token and is used to pay transaction fees, incentivize subnet participants, and for staking. Staking TAO affects how emissions and incentives are allocated (including by influencing validator stake weight and related reward calculations and, under dTAO (defined below), by staking into a subnet’s on-chain pool to receive that subnet’s alpha token) and may affect governance participation. Staking TAO does not itself validate or finalize Subtensor transactions. TAO is, however, also used for governance (including voting power that may be exercised directly or via delegation) and may be used to create/register subnets under protocol rules.

As of November 13, 2026, TAO’s circulating supply was approximately 11.7 million tokens with a market capitalization of approximately $2.53 billion, according to publicly available sources. The lifecycle of TAO follows a supply schedule. Approximately one block is produced every ~12 seconds, with 1 TAO per block minted before the first halving (about 7,200 TAO/day), and 0.5 TAO per block minted after the first halving (about 3,600 TAO/day). The first halving occurred when total issuance reached 10.5 million TAO on December 15, 2025. TAO is not halved on a daily basis. Instead, the per-block emission rate decreases by 50% when predetermined issuance thresholds are reached. TAO has a hard cap of 21,000,000 tokens. Subtensor transaction fees are paid in TAO. Current public documentation indicates that transaction fees are deducted from total issuance rather than distributed as rewards. Accordingly, subnet miners and subnet validators generally do not receive TAO as transaction-fee awards for validating transactions, and instead earn rewards primarily through protocol emissions. In addition, per current documentation, certain staking-related transactions are described as subject to a percentage-based fee (for example, 0.05% of the TAO amount being staked or unstaked), in addition to any weight-based transaction fees (in this context “weight” is a measure of compute time).

Under the February 13, 2025 dTAO upgrade, newly issued TAO is first routed to subnets under protocol rules that, as of November 2025, allocate TAO across subnets based on net TAO inflows from staking activity rather than subnet token prices, and staking into a subnet exchanges TAO for that subnet’s alpha token. Subnet alpha tokens are subnet-specific tokens a participant receives when staking TAO into the subnet’s on-chain market pool, and the alpha token to subnet exchange rate is generally determined by the pool’s reserves. Exits convert alpha tokens back to TAO at the prevailing pool exchange rate at the time of conversion, so outcomes are price sensitive. According to current documentation, emissions for each subnet are generally distributed at the end of every approximately 360 blocks, or about 72 minutes, and the subnet’s participant distribution is generally allocated 41% to miners, 41% to validators and their stakers, and 18% to the subnet owner. The Bittensor blockchain does not impose protocol-enforced delays (unbonding periods) in accessing unstaked TAO. That said, custodians, validators, liquidity pools, or other service providers and operational setups may impose operational, contractual, or practical limits on withdrawal timing or liquidity.

The initial Bittensor mainnet “Kusanagi” launched in January 2021, was followed by the “Nakamoto” upgrade in November 2021, then a fork to the current “Finney” chain on March 20, 2023. Subnets went live on October 2, 2023. Governance has transitioned to a bicameral model in which a Triumvirate (employees of the Opentensor Foundation) authors proposals and a Senate (a group of delegates who have elected to participate in proposals) must approve the proposals prior to implementation. The Senate is comprised of the top delegate hotkeys by stake. In this specific context, a “hotkey” is the operational public key used by a participant to conduct on-chain actions (including by a validator), and a “delegate” is a hotkey that accepts delegated TAO from third parties for staking. “Top” refers to the delegate hotkeys with the highest total stake at a given time. Per current documentation, the Senate has 12 seats (although not all must be filled), and a delegate generally must reach at least 2% of total network stake amount through delegation or self-stake and elect to participate in the Senate. If all twelve Senate seats are filled, and a delegate wishes to join, the lowest stake member is replaced. Because Senate membership is stake-based, governance influence may be concentrated among large stakers and delegates.

32

Table of Contents

​

Our Cryptocurrency Asset Strategy

In June 2025, we adopted a differentiated cryptocurrency treasury strategy focused on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor. Bittensor is a decentralized blockchain network for machine learning and AI. This was a shift from our prior approach of holding excess cash (as defined below) primarily in FDIC-insured interest-bearing accounts. We now seek to allocate substantial portions of our excess cash to purchasing TAO, with the goal of obtaining an increased yield on excess cash by staking TAO for revenue generation and capital appreciation, a strategy that underscores our mission to create significant value for shareholders.

To identify “excess cash,” we first evaluate our cash, cash equivalents, and short-term investments (collectively, “cash assets”). We then estimate the amount of cash assets required to fund approximately 1.5 to 2.0 years of projected operating and working capital needs. Cash assets in excess of this estimated liquidity requirement are considered “excess cash” for purposes of our TAO accumulation strategy. By allocating a substantial portion of our excess cash to TAO, we generally mean that we seek to allocate between 75 percent and 100 percent of this excess cash to the purchase of TAO. However, actual allocation levels may vary due to market conditions, the prevailing price of TAO, liquidity needs, and other factors considered by management.

To guide our cryptocurrency asset purchases, our Board adopted a long-only TAO accumulation strategy and has delegated authority to our Executive Chairman, in consultation with internal personnel and external advisors, to determine the timing, size, and method of TAO purchases with the objective of maximizing tokens per share. Under this authority, management reviews our cash assets, identifies any excess cash as described above, and determines whether to allocate such excess cash to the acquisition of TAO. In addition to using excess cash, our acquisition strategy may also involve issuing debt or equity securities or undertaking other capital raising transactions, subject to market conditions, with the objective of using the proceeds to purchase additional TAO.

We have not established a specific target amount of TAO that we seek to hold. Instead, we monitor market conditions, liquidity needs, and financing opportunities in determining whether to make additional TAO purchases in the future. We view our TAO holdings as long-term holdings and expect to continue accumulating TAO over time. As of September 30, 2026, approximately 95.2% of our treasury holdings were invested in TAO. We do not currently hedge our TAO exposure and have no diversification strategy into other crypto assets. Accordingly, our treasury strategy currently reflects long-only exposure to TAO. However, we are exploring the potential implementation of hedging strategies to manage risks associated with digital asset price volatility; we have not implemented any hedging strategies to date, and there can be no assurance that any such strategies will be implemented or, if implemented, effective.

Although a liquid market for TAO exists, we have not monetized (i.e., sold) any TAO to date. The majority of our TAO is staked as soon as trade settlement permits, and we currently stake TAO through one staking provider, Yuma. We only engage in TAO staking. In the future, we may explore additional yield-enhancement strategies, including participation in Bittensor subnets. Any such activity would likely be undertaken with a third-party partner possessing substantial subnet expertise.

Our Staking Program

We stake our TAO tokens, with the percentage staked varying based on various liquidity and operational considerations, and review this allocation periodically. All staking services are provided through BitGo Bank and Trust, N.A. (formerly known as BitGo Trust Company, Inc.) (the “Custodian”) pursuant to the terms of a Custodial Services Agreement (“CSA”) and the BitGo Staking & Delegation Services Terms (collectively, the “Staking Terms”) which are described below under the heading “Use of Custodians and Storage of TAO Tokens.” In addition, we have entered into a non-custodial Staking & Delegation Technology Services Agreement with Yuma (the “Yuma Agreement”) under which Yuma operates a validator for root subnet staking on the Bittensor network. Yuma does not custody our TAO or any rewards. For 18 months following the effective date of that agreement, we are required to delegate at least 90% of TAO subject to root subnet staking to a Yuma validator.

33

Table of Contents

​

Process of Staking

The Custodian currently supports staking TAO to the Yuma validators pursuant to its Staking Terms. Under these terms, the Custodian or its designated third-party providers, with input from the Company, stake delegated TAO, and exercise any validation rights and voting rights (which do not include protocol governance or voting rights), and distribute net rewards subject to validator service fees. The Bittensor blockchain does not impose protocol-enforced delays or unbonding periods. We do not currently engage in subnet staking or participate in AMM pools, but may do so in the future. Yuma’s role is non-custodial, and its commission rate pursuant to the Yuma Agreement is the publicly posted validator commission on the Bittensor blockchain and may change from time to time.

The Bittensor Network

Bittensor is a public Layer 1 blockchain, called Subtensor, built with the Substrate framework and organized into independent “subnets” where miners produce digital commodities (commonly AI outputs) and validators evaluate them. On chain, an algorithm named Yuma Consensus aggregates validators’ rankings of miners to compute emissions (new tokens minted by the protocol) for miners, validators, stakers, and subnet creators. This incentive mechanism is widely referred to in project materials as “Proof-of-Intelligence.” TAO is the Network’s native token and is used to pay transaction fees, incentivize subnet participants, and for staking.

Validators

We rely on the Custodian to facilitate our staking activities with respect to TAO tokens. Through its staking services, the Custodian holds and stakes our TAO through its selected validator Yuma.

All miner-performance validation in Bittensor occurs within subnets; block/transaction validation occurs on the Subtensor blockchain. Each subnet independently produces the digital commodities that are its focus, with the subnet creator defining an incentive mechanism for validators to use in judging miners’ work. Validators apply this incentive mechanism to miners, score their performance, and submit these weights to the Bittensor blockchain. These validator scores are then used by the Yuma Consensus algorithm to determine the proportion of the subnet’s emissions that should be allocated to each miner.

Each validator submits its rankings of miners it has evaluated to the Bittensor blockchain. The algorithm then considers all these rankings and seeks to identify which validators appear to provide the most reliable evaluations. Validators whose rankings appear to consistently align with those of other validators should gain more influence in the system, while validators that submit less reliable evaluations are expected to lose influence.

How We Earn Staking Rewards

As holders of TAO tokens we can stake any amount of the liquidity we hold to a validator. Also known as “delegation”, staking supports validators, because their total stake in the subnet, including stake delegated to them by others, determines their consensus power and their share of emissions. After the validator extracts their take, the remaining emissions are credited back to us in proportion to our stake with that validator. We stake TAO tokens through arrangements facilitated and managed by the Custodian and its selected validator Yuma. For a further discussion of the risks related to staking, see “Risk Factors-Risks Related to Staking” elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025.

Use of Custodians and Storage of TAO Tokens

In June 2025, we entered into a CSA with the Custodian, which is a national trust bank chartered and regulated by the Office of the Comptroller of the Currency and licensed to act as a custodian, for a six-month initial term with automatic six-month renewals unless terminated. Termination may occur for convenience with 60 days’ prior written notice or for breach with 30 days’ notice. Assets held under the agreement are generally maintained in segregated custodial accounts, separate from the Custodian’s own assets and other clients’ assets per the CSA. The Custodian provides quarterly electronic account statements and, upon request, will confirm asset holdings. To value TAO held in our account, the Custodian electronically obtains USD equivalent prices from digital asset market data with amounts rounded up to the seventh decimal place to the right. Insurance coverage maintained by the Custodian is described further below. Access to the Company’s custodial account holding TAO is generally limited to persons designated by us through the Custodian’s user interface. The Prime Broker (defined below) is permitted limited access to the Company’s custodial account solely to facilitate the execution of trades of TAO.

34

Table of Contents

​

In June 2025, we also entered into a Master Purchase Agreement (“MPA”) with BitGo Prime LLC (the “Prime Broker”), which is a Delaware limited liability company, to facilitate digital asset trading through the Prime Broker’s proprietary electronic trading system. The agreement operates on a principal-to-principal basis, with each party acting for its own account and not as agent or fiduciary to the other party. All transactions are settled through, and custodied at, the Custodian under the CSA described herein. The Custodian maintains sole and exclusive custody of the Company’s TAO at all times, including during the pendency of trading activity by the Prime Broker. Notwithstanding the Company’s use of the Prime Broker to facilitate trading activities, the Prime Broker does not at any time take custody, possession, or control of the Company’s TAO assets. Pursuant to the MPA, upon confirmation of a trade, settlement occurs on a delivery-versus-payment basis, whereby the Prime Broker facilitates the simultaneous exchange of U.S. dollars from the Company’s custodial account maintained with the Custodian in consideration for the delivery of the corresponding TAO tokens to such account. This settlement mechanism is designed to mitigate counterparty risk by ensuring that the transfer of funds and digital assets occurs concurrently and that the Company’s TAO assets remain in the custody of the Custodian throughout the transaction lifecycle. Access to the Company’s trading account is generally restricted to users it designates. The Prime Broker uses the Custodian’s balance inquiry functionality to verify the existence of sufficient assets before executing trades. The MPA terminates automatically upon termination of the CSA, and the Prime Broker reserves the right to suspend or modify services at its discretion.

The TAO Daily

On September 22, 2025, we announced the launch of The TAO Daily, our comprehensive media, news, and insight platform dedicated to Bittensor (TAO) and the TAO ecosystem. The TAO Daily platform aims to highlight the Bittensor ecosystem developments and provide transparency into the rapidly growing world of decentralized AI. The platform also aims to centralize resources useful to TAO users and investors. Additionally, a new podcast, The TAO Pod, is hosted by James Altucher and Joseph Jacks, well-known TAO ecosystem leader and crypto treasury advisor to the Company.

Series B Common Stock Warrants

Pursuant to a November 17, 2022 private placement, the Company issued to investors warrants and, pursuant to its advisory agreements, the Company issued to its advisor additional warrants with the same terms to purchase 2,323 shares of Common Stock with the same terms (the “Series B Broker Warrants”). The Series B Broker Warrants are within the scope of ASC 718 pursuant to ASC 718-10-20 but are subject to liability classification as they would be required to be classified as liabilities in accordance with ASC 480.

The warrants were determined to be within the scope of ASC 480-10 as they are puttable to the Company at the Holders’ election upon the occurrence of a Fundamental Transaction (as defined in the agreements). As such, the Company recorded the warrants as a liability at fair value with subsequent changes in fair value recognized in earnings.

During the three months ended September 30, 2026 and 2025, the Company recorded a loss of $1,000 and a gain of $106,000, respectively, and, during the nine months ended September 30, 2026 and 2025, the Company recorded a loss of $1,000 and $336,000, respectively, related to the change in fair value of the Series B warrant liability, which is recorded in other income (expense) on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The fair value of the warrants of approximately $10,000 was estimated at September 30, 2026 utilizing the Black Scholes model using the following weighted average assumptions: dividend yield 0%; remaining term of 1.14 years; equity volatility of 110.0%; and a risk-free interest rate of 4.49%.

Series D and Series E Warrants Repricing

On May 18, 2026, the Company issued stock options to certain Company officers and directors with an exercise price of $4.80 per share. As a result, the Company issued, to holders of the Series E Warrants, an additional 953,335 warrants pursuant to the repricing triggered by the options issuance and repriced the Series E Warrants to $4.80 per share. On July 6, 2026, the Company issued warrants to a consultant with an exercise price of $3.85 per share. As a result, the Company issued to holders of the Series E Warrants an additional 588,098 warrants and repriced the Series E Warrants to $3.85 per share. On November 13, 2026, the Company repriced a number of warrants to purchase Common Stock previously issued to Z-List Media, Inc. to an exercise price of $2.10 per share. As a result, the Company repriced the Series D Warrants to $2.10 per share and repriced the Series E Warrants to $2.10 per share.

35

Table of Contents

​

Other Development Projects

To the extent resources permit, we may pursue development of selected technology platforms with indications related to the treatment of various disorders, including neurodegenerative disorders such as AD, based on our currently licensed technology and/or technologies available from third party licensors or collaborators.

Nemours Agreement

On September 5, 2018, we announced a collaboration with Nemours, a premier U.S. children’s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, we announced our memorandum of understanding with Nemours to initiate a clinical trial using Bryostatin-1, under orphan drug status, to treat Fragile X. We intend to provide the Bryostatin-1 drug product candidate and obtain the IND and Nemours intends to provide the clinical site and attendant support for the trial. We and Nemours, jointly, will develop the trial protocol. We currently estimate our total trial and IND cost to be approximately $2 million. As of the end of the period covered by this quarterly report, we have incurred cumulative expenses associated with this agreement of approximately $100,000.

We have filed for an IND with the FDA. The FDA has placed the development of the IND on clinical hold pending completion of further analytics relating to drug pharmacokinetics and pharmacodynamics. We are currently evaluating our plans to advance Fragile X development.

Critical Accounting Estimates

There have been no material changes to our critical accounting estimates from those described in our Annual Report on Form 10-K for the year ended December 31, 2025.

Results of Operations

Comparison of the three months ended September 30, 2026 and 2025

The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months ended

​

​

​

​

​

 

​

​

September 30, 

​

Dollar

​

​

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Change

  ​ ​ ​

% Change

 

Revenues

​

$

245,724

​

$

203,371

​

$

42,353

​

20.8

%

Operating Expenses:

​

 

  ​

​

 

  ​

​

 

​

 

  ​

​

Research and development expenses

​

$

29,814

​

$

54,388

​

$

(24,574)

​

(45.2)

%

General and administrative expenses

​

$

1,900,816

​

$

1,948,483

​

$

(47,667)

​

(2.4)

%

Other income (expense), net

​

$

8,143,459

​

$

(2,123,747)

​

$

10,267,206

​

NA

​

Net income (loss)

​

$

6,458,553

​

$

(3,923,247)

​

$

10,381,800

​

NA

​

Net comprehensive income attributable to common stockholders

​

$

4,062,297

​

$

(3,968,457)

​

$

8,030,754

​

NA

​

​

Revenues

We generated operating revenues for the three months ended September 30, 2026 and 2025 from staking TAO tokens of $245,724 and $203,371, respectively. The increase is primarily attributable to a larger number of TAO tokens staked and earned during the 2026 period (approximately 1,098 tokens versus 667 tokens), partially offset by a lower average TAO price at the time the rewards were received.

36

Table of Contents

​

Operating Expenses

Overview

Total operating expenses for the three months ended September 30, 2026 were $1,930,630 as compared to $2,002,871 for the three months ended September 30, 2025, a decrease of approximately 3.6%. The decrease in total operating expenses is due to the decreases in research and development and general and administrative expenses.

Research and Development Expenses

For the three months ended September 30, 2026, we incurred $29,814 in research and development expenses as compared to $54,388 for the three months ended September 30, 2025, a decrease of approximately 45.2%. These expenses were incurred primarily in connection with developing the potential AD therapeutic product. Of these expenses, for the three months ended September 30, 2026, $20,936 was incurred principally relating to our storage of drug product, $0 for clinical consulting services, $2,878 of amortization of prepaid licensing fees relating to the Stanford License Agreement, $6,000 for development of alternative drug supply with Stanford University; comparatively, for the three months ended September 30, 2025, $27,305 was incurred principally relating to our product development and storage of drug product, $13,279 for clinical consulting services, $7,534 of amortization of prepaid licensing fees relating to the Stanford License Agreement and the Mount Sinai License Agreement, and $6,270 for development of alternative drug supply with Stanford University.

Our research and development expenses have decreased as our Cleveland Clinic trial for AD was concluded by the end of 2024 and our MS clinical trial was discontinued. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.

General and Administrative Expenses

We incurred $1,900,816 and $1,948,483 of general and administrative expenses for the three months ended September 30, 2026 and 2025, respectively, a decrease of approximately 2.4%. For the three months ended September 30, 2026, $271,013 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $212,341 for the three months ended September 30, 2025. The increase resulted primarily from increased compensation for the Company’s Chairman as he became Executive Chairman during the second quarter of 2025; $103,795 was incurred for legal expenses versus $403,789 for the 2025 comparable period. The higher legal fees for 2025 are based upon the Company changing its business strategy, restructuring and financing; $745,741 was incurred for outside operations consulting services during the three months ended September 30, 2026, versus $785,385 for the comparable period in 2025; $6,425 was incurred for travel expenses during the three months ended September 30, 2026, versus $12,502 for the comparable period in 2025 as Company officers and directors conducted due diligence for strategic investments in 2025; $47,779 was incurred for investor relations services during the three months ended September 30, 2026, versus $105,379 for the comparable period in 2025. The 2025 period included additional IR consulting services for the Company’s change to cryptocurrency treasury strategy; $60,926 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services during the three months ended September 30, 2026, versus $54,310 for the comparable period in 2025; $172,767 was incurred for insurance during the three months ended September 30, 2026, versus $144,913 for the comparable period in 2025. The increase is attributable to higher premiums relating to the Company’s cryptocurrency treasury strategy; $110,055 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other during the three months ended September 30, 2026, versus $176,090 for the comparable period in 2025. The higher fees for 2025 represent SEC filing fees for financings conducted during the period; and $382,335 was recorded as non-cash stock options compensation expense during the three months ended September 30, 2026, versus $53,774 for the comparable period in 2025. The increase for the current period is attributable to granting of stock options awards during the second quarter of 2026.

Other Income / Expense

We recognized total other income of $8,143,459 for the three months ended September 30, 2026 as compared to other expenses of $2,123,747 for the three months ended September 30, 2025, which consisted, for the periods 2026 and 2025, of unrealized gains and losses on digital assets, and for both 2026 and 2025, interest income on funds deposited in interest-bearing money market accounts and investments in short-term U.S. treasury bills, and changes in fair value of warrant and derivative liabilities. The decrease in interest income and unrealized gains on treasury bills totaling $32,207 is primarily attributable to the decrease in cash balances over the period and lower interest rates. The total increase in other income is primarily attributable to the unrealized gain on digital asset investments of approximately $10.7 million, gains attributable to the Yuma partnership investments of $278,708 partially offset by the increase in the fair values of warrant and derivative liabilities of approximately $686,000 and the decrease in interest income as noted above.

37

Table of Contents

​

Net Income / Loss

We recognized net income of $6,458,553 versus a loss of $3,923,247 for the three months ended September 30, 2026 and 2025, respectively. The change was primarily attributable to the $8.3 million unrealized gain on digital assets in the 2026 period compared to a $2.4 million unrealized loss in the 2025 period.

Comparison of the nine months ended September 30, 2026 and 2025

The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months ended

​

​

​

​

​

 

​

​

September 30, 

​

Dollar

​

%

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Change

  ​ ​ ​

Change

 

Revenues

​

$

723,124

​

$

207,333

​

$

515,791

 

248.8

%

Operating Expenses:

​

 

  ​

​

 

  ​

​

 

  ​

 

  ​

​

Research and development expenses

​

$

90,269

​

$

263,759

​

$

(173,490)

 

(65.8)

%

General and administrative expenses

​

$

5,204,761

​

$

5,148,227

​

$

56,534

 

1.1

%

Warrant issuance costs

​

$

—

​

$

699,845

​

$

(699,845)

 

(100.0)

%

Other income, net

​

$

5,985,885

​

$

(15,149,658)

​

$

21,135,543

 

NA

​

Net income (loss)

​

$

1,413,979

​

$

(21,054,156)

​

$

22,468,135

 

NA

​

Net comprehensive loss attributable to common stockholders

​

$

(5,544,706)

​

$

(21,303,508)

​

$

15,758,802

 

NA

​

​

Revenues

We generated operating revenues for the nine months ended September 30, 2026 and 2025 from staking TAO tokens of $723,124 and $207,333, respectively. The increase is principally attributable to purchasing tokens and staking for the entire 2026 period versus limited purchases and staking in the 2025 period.

Operating Expenses

Overview

Total operating expenses for the nine months ended September 30, 2026 were $5,295,030 as compared to $6,111,831 for the nine months ended September 30, 2025, a decrease of approximately 13.4%. The decrease in total operating expenses is due to the decreases in research and development expenses and warrant issuance costs partially offset by the increase in general and administrative expenses.

Research and Development Expenses

For the nine months ended September 30, 2026, we incurred $90,269 in research and development expenses as compared to $263,759 for the nine months ended September 30, 2025, a decrease of approximately 65.8%. These expenses were incurred primarily in connection with developing the potential AD therapeutic product. Of these expenses, for the nine months ended September 30, 2026, $41,640 was incurred principally relating to our storage of drug product, $9,525 for clinical consulting services, $13,153 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai License Agreement (discontinued in Q2 2026), $25,951 for development of alternative drug supply with Stanford University; comparatively, for the nine months ended September 30, 2025, $137,953 was incurred principally relating to our product development and storage of drug product, $70,362 for clinical consulting services, $22,438 of amortization of prepaid licensing fees relating to the Stanford License Agreement and the Mount Sinai License Agreement, and $33,006 for development of alternative drug supply with Stanford University.

Our research and development expenses have decreased as our Cleveland Clinic trial for AD was concluded by the end of 2024 and our MS clinical trial was discontinued. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.

38

Table of Contents

​

General and Administrative Expenses

We incurred $5,204,761 and $5,148,227 of general and administrative expenses for the nine months ended September 30, 2026 and 2025, respectively, an increase of approximately 1.1%. For the nine months ended September 30, 2026, $808,093 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $662,132 for the nine months ended September 30, 2025. The increase resulted primarily from increased compensation for the Company’s Chairman as he became Executive Chairman during the second quarter of 2025; $403,115 was incurred for legal expenses versus $804,746 for the 2025 comparable period. The higher legal fees for 2025 are based upon the Company changing its business strategy, restructuring and financing; $1,924,563 was incurred for outside operations consulting services during the nine months ended September 30, 2026, versus $1,290,215 for the comparable period in 2025. The higher amount for the 2026 period reflects non-cash expenses associated with warrants issued to cryptocurrency experts totaling $1,194,918; $24,694 was incurred for travel expenses during the nine months ended September 30, 2026, versus $38,831 for the comparable period in 2025 as Company officers and directors conducted due diligence for strategic investments in 2025; $285,892 was incurred for investor relations services during the nine months ended September 30, 2026, versus $309,814 for the comparable period in 2025; $199,467 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services during the nine months ended September 30, 2026, versus $195,022 for the comparable period in 2025; $503,669 was incurred for insurance during the nine months ended September 30, 2026, versus $424,848 for the comparable period in 2025. The increase is attributable to higher premiums relating to the Company’s cryptocurrency treasury strategy; $354,608 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other during the nine months ended September 30, 2026, versus $395,904 for the comparable period in 2025; and $700,660 was recorded as non-cash stock options compensation expense during the nine months ended September 30, 2026, versus $1,026,715 for the comparable period in 2025. The decrease for the current period is attributable to granting of restricted stock awards during the third quarter of 2025 partially offset by the issuance of stock options awards during the second quarter 2026.

Warrant Issuance Costs

The nine months ended September 30, 2025 results included warrant issuance costs associated with the Series D Private Placement of approximately $700,000.

Other Income / Expense

We recognized total other income of $5,985,885 for the nine months ended September 30, 2026 as compared to other expenses of $15,149,658 for the nine months ended September 30, 2025, which consisted, for the periods 2026 and 2025, of unrealized gains for 2026 and unrealized losses for 2025 on digital assets, interest income on funds deposited in interest-bearing money market accounts and investments in short-term U.S. treasury bills, and changes in fair value of warrant and derivative liabilities. The decrease in interest income and unrealized gains on treasury bills totaling $306,605 is primarily attributable to the decrease in cash balances over the period and lower interest rates. The total increase in other income is primarily attributable to the decrease in the fair values of warrant and derivative liabilities of approximately $12.0 million, income attributable to the Yuma partnership investments of $310,578 and unrealized gain on digital asset investments of approximately $9.1 million, partially offset by the decrease in interest income as noted above.

Net Income / Loss

We recognized net income of $1,413,979 versus a loss of $21,054,156 for the nine months ended September 30, 2026 and 2025, respectively. The increase in income was primarily attributable to the decrease in research and development and increase in other income, partially offset by the increase in general and administrative expenses.

Financial Condition, Liquidity and Capital Resources

Cash and Working Capital

Since inception, we have incurred negative cash flows from operations. As of September 30, 2026, we had working capital of $26,426,907 as compared to working capital of $23,564,919 as of December 31, 2025. The $2,861,988 increase in working capital was primarily attributable to the increase of digital assets of approximately $7.5 million, approximately $580,000 from consultant warrant issuances and approximately $72,000 from interest income, partially offset by approximately $5.3 million of operating expenses and approximately $770,000 of preferred stock dividend payments.

39

Table of Contents

​

We expect that our current cash and cash equivalents and digital assets of approximately $16.7 million will be sufficient to support our projected operating requirements for at least the next 12 months from the date of this Quarterly Report on Form 10-Q, which may include the continuing development of Bryostatin-1 and other possible therapeutics.

We expect to require additional capital in order to initiate, pursue and complete all potential AD clinical trials and obtain regulatory approval of one or more therapeutic candidates. However, additional future funding may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed, we may not be able to initiate, pursue and complete all planned clinical trials or continue the development of our product candidates or we could be required to delay, scale back or eliminate some or all of our development programs and operations. Any additional equity financing, if available, may not be available on favorable terms, would most likely be significantly dilutive to our current stockholders and debt financing, if available, and may involve restrictive covenants. If we are able to access funds through collaborative or licensing arrangements, we may be required to relinquish rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize on our own, on terms that are not favorable to us. Our ability to access capital when needed is not assured and, if not achieved on a timely basis, would likely materially harm our business and financial condition.

Material Cash Requirements Our material cash requirements include the potential redemption of the Series D Convertible Preferred Stock ($679,000 aggregate stated value) and the Series E Convertible Preferred Stock ($9,053,000 aggregate stated value plus $188,642 of accrued dividends), the Executive Chairman’s annual base salary of $360,000 under the Silverman Compensation Agreement, and our commitments under the Yuma Agreement. We expect to fund these requirements from cash on hand and, if necessary, sales of TAO, which we have not undertaken to date and which may occur at prices below current market prices.

Sources and Uses of Liquidity

We expect to continue to incur expenses, resulting in losses and negative cash flows from operations, over at least the next several years as we continue to develop AD and other therapeutic products along with developing our crypto treasury strategy. We anticipate that this development may include clinical trials in addition to our additional research and development expenditures.

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Cash used in operating activities

​

$

3,448,132

​

$

3,944,213

Cash used in investing activities

​

$

—

​

$

17,570,203

Cash (used in) provided by financing activities

​

$

(768,300)

​

$

5,303,622

​

Net Cash Used in Operating Activities

Cash used in operating activities was $3,448,132 for the nine months ended September 30, 2026, compared to $3,944,213 for the nine months ended September 30, 2025. The $496,081 decrease primarily resulted from the decrease in net loss of approximately $22.5 million, the increase in non-cash compensation of approximately $227,000 and the increase in current assets and liabilities of approximately $460,000, partially offset by the decrease in derivative and warrant liabilities of approximately $12.0 million, the increase in gains and non-cash revenue from digital assets of approximately $9.6 million and the decrease in warrant issuance costs of approximately $700,000, and the increase in value of Yuma partnership investments of approximately $310,000.

Net Cash Provided by (Used in) Investing Activities

Net cash used in investing activities was $0 for the nine months ended September 30, 2026 compared to approximately $17.6 million for the nine months ended September 30, 2025. The cash used for the nine months ended September 30, 2025 was for the purchase of crypto currency for the Company’s treasury strategy.

40

Table of Contents

​

Net Cash Provided by / Used in Financing Activities

Net cash used in financing activities was $768,300 for the nine months ended September 30, 2026 compared to cash provided by financing activities of $5,303,622 for the nine months ended September 30, 2025. For the nine months ended September 30, 2026, the entire amount was used to pay dividends on Convertible Preferred Stock. For the nine months ended September 30, 2025 consisted of proceeds from the Company’s Series D Preferred Stock offering and proceeds from exercise of investor warrants partially offset by principal and dividend payments applied to our outstanding Series C Preferred Stock outstanding.

​

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable to a smaller reporting company.

​

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and our principal financial and accounting officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on their evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures are not effective due to: inadequate segregation of duties consistent with control objectives in the areas over certain payroll and banking systems and user access controls; ineffective processes over period end financial disclosure and reporting including documentation of GAAP disclosure and reporting reviews supporting the financial reporting process and changes to chart of accounts; and ineffective information technology (IT) general computing controls including lack of risk and design assessments supporting IT security policies and procedures, user access, and IT controls within third party contracts. These weaknesses may affect management’s ability to determine if errors or inappropriate actions have taken place. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible changes in our disclosure controls and procedures.

We previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, that our management, including our principal executive officer and principal financial and accounting officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and SEC guidance on conducting such assessments. Based on that evaluation, management concluded that, as of December 31, 2025, our internal control over financial reporting was not effective.

Based on management’s review, our Executive Chairman of the Board and Chief Financial Officer concluded that our disclosure controls and procedures were ineffective as of September 30, 2026. Notwithstanding the material weaknesses described above, our management has concluded that financial statements, and other financial information included in this Quarterly Report on Form 10-Q, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this Quarterly Report on Form 10-Q.

Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the quarter ended September 30, 2026, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Remediation Efforts Management continues to evaluate and implement measures to remediate the material weaknesses described above, including steps taken or planned, such as additional segregation of duties, enhanced period-end review procedures and IT general control improvements.

​

41

Table of Contents

​

PART II

OTHER INFORMATION

Item 1. Legal Proceedings.

None.

​

Item 1A. Risk Factors.

You should carefully review and consider the information regarding certain factors that could materially affect our business, condensed consolidated financial condition or results of operations set forth under Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Except as set forth below, there have been no material changes from the risk factors disclosed in such Form 10-K. The risk factors set forth below update, and should be read together with, the risk factors disclosed in such Form 10-K. We may disclose changes to risk factors from time to time in our future filings with the SEC.

Risks Related to Our Digital Asset Strategy and Holdings

Bittensor’s TAO token, generated via a decentralized “Proof-of-Intelligence” mining process, faces significant volatility, governance centralization risks, regulatory uncertainty, limited liquidity, and ongoing security vulnerabilities related to its AI-focused consensus model and underlying decentralized infrastructure.

Bittensor’s native token, TAO, was launched via a “fair launch” mining process in January 2021 and, according to public reports, without a pre-sale, ICO, or pre-mined allocation. Circulating tokens were earned by miners, promoting decentralization but potentially resulting in wealth concentration among early participants. The project is managed by the Opentensor Foundation, a small team of developers, making it heavily dependent on their ongoing involvement. Until early 2024, governance power was concentrated in a small number of validators, posing centralization risks. Although Bittensor documentation describes a bicameral Triumvirate and Senate governance model and the dTAO upgrade was implemented in February 2025, protocol changes are currently executed through a privileged administrative key controlled by a small number of signers, as described under “Background on TAO and Bittensor” in Part I, Item 2 of this Quarterly Report on Form 10-Q, and these arrangements remain relatively untested and could present unforeseen challenges and conflicts of interest.

TAO tokens are generated through Bittensor’s “Proof-of-Intelligence” consensus mechanism, where validators assess AI contributions from miners to distribute rewards. This approach, however, introduces potential vulnerabilities such as subjective evaluations, collusion, and technical security risks. Notably, in July 2024, a supply-chain attack led to theft of private keys and prompted a temporary network shutdown, underscoring existing security concerns and highlighting the network’s reliance on centralized emergency controls.

TAO has a capped supply of 21 million tokens. The first halving of the per-block emission rate occurred on December 15, 2025, when total issuance reached 10.5 million TAO, and subsequent halvings will occur when further predetermined issuance thresholds are reached. These dynamics could influence miner incentives and affect market liquidity. TAO’s value is speculative and highly dependent on future adoption and ecosystem growth. Trading liquidity is limited and primarily concentrated on offshore exchanges, increasing price volatility and counterparty risks. Currently, derivatives markets for TAO are limited, and while products such as the Grayscale Bittensor Trust may enhance market accessibility, they carry additional liquidity and regulatory uncertainties.

42

Table of Contents

​

Bittensor, a decentralized AI blockchain network using a “Proof-of-Intelligence” consensus model tied to subnet output evaluation and performance for purposes of allocating token emissions and incentives (distinct from Subtensor’s separate mechanism for ordering transactions and finalizing blocks), faces significant technical, operational, scalability, governance, and regulatory risks, including dependence on third-party off-chain infrastructure, potential vulnerabilities in AI validation processes, limited scalability, decentralized governance inefficiencies, and regulatory uncertainties, all of which could adversely impact the value and adoption of its native TAO token.

TAO functions on the Bittensor network, which operates as a decentralized AI network built on a custom blockchain utilizing the Substrate framework and employs a novel consensus mechanism commonly referred to as “Proof-of-Intelligence,” whereby subnet output evaluation (and the resulting token emission and incentive allocations) are tied to performance within specialized subnets. This Proof-of-Intelligence consensus mechanism is distinct from Subtensor’s separate mechanism for transaction ordering and block finality. The complex architecture of this system introduces significant technical and operational risks. Given the sophisticated blockchain infrastructure and Bittensor’s specialized AI-focused subnets, there exists a heightened potential for software errors, system vulnerabilities, and unforeseen operational disruptions. Such events could result in extended network downtime, diminished user confidence, or even irreversible losses of digital assets.

Moreover, Bittensor heavily depends on off-chain infrastructure for executing AI computations, leading to inherent trust and transparency issues. Users must rely on third-party providers to execute AI tasks accurately and securely. Any inaccuracies, misreporting, malicious actions, or operational failures in these off-chain processes could significantly damage the reliability and overall reputation of the Bittensor network and negatively impact the TAO token’s value.

The decentralized nature of Bittensor further presents notable scalability challenges. As participation increases, the complexity and resource-intensiveness of validating and evaluating AI model contributions can create bottlenecks and degrade system performance. These scalability constraints could prevent Bittensor from effectively competing with centralized AI platforms, potentially limiting widespread adoption and constraining growth in demand for the TAO token.

In addition, maintaining robust quality control and verifying AI outputs within the Bittensor ecosystem pose ongoing challenges. While the platform employs a competitive, reputation-based reward system to incentivize quality contributions, this structure remains vulnerable to risks such as validator collusion, sabotage among competing model providers, and manipulation of reputation or reward mechanisms. Without robust on-chain verification processes, incorrect or deceptive AI outputs may proliferate, eroding trust and undermining the perceived value of services provided through the network.

The value and liquidity of the TAO token also depend substantially on its adoption among developers, researchers, and other users within decentralized AI markets. If Bittensor fails to expand beyond niche communities or becomes overshadowed by centralized AI alternatives, it may experience decreased demand for its services. This scenario would negatively impact the market price and liquidity of TAO, adversely affecting our financial position.

Bittensor’s governance arrangements, under which protocol changes are currently executed through a privileged administrative key rather than by a vote of TAO holders, also introduce additional risks related to decision-making delays, political friction, and governance inefficiencies. Regulatory ambiguity and increased scrutiny surrounding decentralized AI systems and crypto tokens further compound these governance challenges. Adverse regulatory actions, unclear legal interpretations, or new compliance obligations could impose substantial additional costs or operational restrictions or potentially force cessation of certain business activities altogether. This regulatory uncertainty could also deter institutional adoption and broader acceptance of Bittensor, further limiting its potential growth and stability.

Collectively, these technical, operational, market, governance, and regulatory risks could result in substantial volatility in the value of TAO, materially affecting our business strategy involving this asset.

43

Table of Contents

​

In addition, Subtensor currently uses a proof-of-authority model under which a small, permissioned set of validators operated by the Opentensor Foundation produces and finalizes blocks. By contrast, Yuma Consensus is an on-chain emissions algorithm that computes reward allocations from validator rankings of model performance and does not provide transaction ordering, block production, or ledger finality. Reliance on this authority set centralizes transaction ordering and finality and increases the risk of network halts, delayed processing, or selective censorship if operators fail, are compromised, or change policies. Compromise or misuse of authority signing keys, software defects, or misconfiguration may require emergency coordination or restricted operating modes and could disrupt our ability to acquire, transfer, or dispose of TAO, potentially triggering exchange or custodian pauses, reduced liquidity, wider spreads, and price volatility. Concentration at the authority layer also creates a single point of operational and regulatory leverage: legal orders, sanctions, or jurisdictional restrictions directed at the Foundation or authority operators could compel blocking, reordering, or exclusion of transactions or participants. The composition, permissions, and parameters of the authority set may change on short notice, and elevated security and key-management demands increase the risk of downtime or reorganizations; authority control can also amplify governance disputes. Collectively, these factors may impair network reliability and perceived decentralization, reduce adoption and TAO liquidity, and adversely affect our business, financial condition, and results of operations.

Our operating results are dependent on the price of TAO. If such price declines, our business, operating results, and financial condition would be adversely affected.

Any declines in the volume of crypto asset transactions, the price of crypto assets, or market liquidity for crypto assets generally may adversely affect our operating results. We have significant investments in TAO. As of October 23, 2026, we held digital assets valued at approximately $22.0 million. Thus, changes in the value of TAO will generally have a significant impact on our results. Our operating results will be impacted by the revenues and profits we generate from the purchase, sale, and trading of crypto assets.

The market price of Bittensor’s TAO token has been highly volatile and could decline sharply at any time. For example, TAO’s price experienced a rise of over 1000% in 2024, reaching a high above $767 in April 2024, and subsequently declined by approximately 60% from that peak as of October 1, 2026. Such extreme fluctuations could significantly increase or reduce the value of our TAO holdings within a short period. The market price of TAO can be driven by a variety of factors beyond our control, including speculative investor behavior, regulatory developments, changes in market liquidity, the adoption and performance of the Bittensor network, cybersecurity incidents, macroeconomic events, or negative publicity about digital assets generally or TAO specifically. Because we have invested a substantial portion of our treasury in TAO, a major downturn in TAO’s market price could materially impair the value of our assets and even jeopardize our ability to meet cash needs or financial obligations.

The price of crypto assets and associated demand for buying, selling, and trading of crypto assets have also historically been subject to significant volatility. For instance, in 2017 and 2021, the value of certain crypto assets, including bitcoin, experienced steep increases in value, followed by steep declines in 2018 and 2022. After recovering from the 2018 decline and reaching record highs in December 2021, the value of the total crypto market cap declined by approximately 64% in the twelve months ended December 31, 2022. The collapse of several companies in the crypto asset industry such as Celsius, Voyager, and FTX impacted crypto asset prices in 2022 and the majority of 2023. We believe that the approval and launch of spot-based Bitcoin ETFs in the U.S. in the first quarter of 2024 and the election of President Donald Trump in the fourth quarter of 2024 contributed to an increase in the crypto market capitalization during 2024. However, although the crypto market reached a peak during mid-2025, they subsequently experienced a general decline and ended the year below such peak levels. The price and trading volume of any crypto asset is subject to significant uncertainty and volatility, and may significantly decline in the future, without recovery. Such uncertainty and volatility depend on a number of factors, including:

●market conditions across the cryptoeconomy;
●changes in liquidity, volume, and trading activities;
●trading activities on crypto asset trading platforms worldwide, many of which may be unregulated, and may include manipulative activities;
●investment and trading activities of highly active retail and institutional users, speculators, miners, and investors;
●the speed and rate at which cryptocurrency is able to gain adoption as a medium of exchange, utility, store of value, consumptive asset, security instrument, or other financial asset worldwide, if at all;
●decreased user and investor confidence in crypto assets and crypto asset trading platforms;
●negative publicity and events relating to the cryptoeconomy;
●unpredictable social media coverage or “trending” of crypto assets;
●the ability for crypto assets to meet user and investor demands;

44

Table of Contents

​

●the functionality and utility of crypto assets and their associated ecosystems and networks, including crypto assets designed for use in various applications;
●consumer preferences and perceived value of crypto assets and crypto asset markets;
●increased competition from other payment services or other crypto assets that exhibit better speed, security, scalability, or other characteristics;
●regulatory (including enforcement) or legislative changes and updates affecting the cryptoeconomy;
●the characterization of crypto assets under the laws of various jurisdictions around the world;
●the maintenance, troubleshooting, and development of the blockchain networks underlying crypto assets, including by miners, validators, and developers worldwide;
●the ability for cryptocurrency networks to attract and retain miners or validators to secure and confirm transactions accurately and efficiently;
●ongoing technological viability and security of crypto assets and their associated smart contracts, applications, and networks, including vulnerabilities against hacks and scalability;
●fees and speed associated with processing crypto asset transactions, including on the underlying blockchain networks and on crypto asset trading platforms;
●financial strength of market participants;
●the availability and cost of funding and capital;
●the liquidity of crypto asset trading platforms;
●interruptions in service from or failures of major crypto asset trading platforms;
●availability of an active derivatives market for various crypto assets;
●availability of banking and payment services to support cryptocurrency-related projects;
●level of interest rates and inflation;
●monetary policies of governments, trade restrictions, and fiat currency devaluations; and
●national and international economic and political conditions.
●Furthermore, crypto asset prices may be subject to market manipulation or distortion, including pump-and-dump schemes, wash trading, spoofing, and front-running, particularly on unregulated exchanges. Such manipulation could significantly impact the perceived value and trading volume of TAO and undermine investor confidence in the crypto asset market, adversely affecting our business.
●There is no assurance that any crypto asset will maintain its value or that there will be meaningful levels of trading activities. In the event that the price of crypto assets or the demand for trading crypto assets decline, our business, operating results, and financial condition could be adversely affected.

We are highly dependent on James Altucher and other key personnel, and our inability to retain or attract experienced individuals could materially harm our business.

We are highly dependent on the services of our TAO token consultant, James Altucher, for leading our TAO-based revenue generation strategy. Because we operate in a relatively new industry that requires highly skilled and technical personnel, our future success is highly dependent on the talents and contributions of Mr. Altucher. The loss of Mr. Altucher could disrupt our operations and have a material adverse effect on our business. Mr. Altucher is free to engage in activities outside of the Company, although he is obligated under his consulting agreement to devote his TAO-related activities exclusively to us. While Mr. Altucher has provided services to the Company under a consulting arrangement that currently extends through June 8, 2029, he is not expected to devote his full time, attention or efforts to us. Mr. Altucher may continue to manage significant crypto assets outside of the Company, which may consume some of his time, attention and efforts. In addition, we cannot assure investors that the consulting agreement will be renewed or extended beyond its current term.

Additionally, our future growth and success depend on our ability to attract, retain, and motivate skilled employees and contractors in the crypto asset industry. Competition for qualified personnel in the crypto asset and blockchain industries is intense. The specialized nature of blockchain technology and crypto asset markets means there is limited availability of highly experienced personnel. Our growth strategy depends not only on retaining key individuals like Mr. Altucher but also on our ability to attract and retain additional experienced professionals. Any inability to secure or retain such personnel due to competitive pressures, reputational factors, regulatory uncertainty, or market conditions could adversely impact our ability to execute our strategic initiatives and could materially harm our business.

45

Table of Contents

​

Regulatory change classifying certain digital cryptocurrency assets as “securities” could lead to our being subject to extensive regulation, which could result in significant costs or force us to cease operations.

Under Sections 3(a)(1)(A) and (C) of the Investment Company Act of 1940, as amended (the “1940 Act”), a company generally will be deemed to be an “investment company” for purposes of the 1940 Act if (1) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (2) it is engaged, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. We do not believe that we are an “investment company,” as such term is defined in the 1940 Act, and are not registered as an “investment company” under the 1940 Act as of the date hereof.

The legal and regulatory status of digital assets under U.S. federal and state securities laws remains uncertain and continues to evolve. Although the staff of the Commission’s Division of Corporation Finance has issued statements and responses to frequently asked questions regarding the application of the federal securities laws to certain crypto assets and related activities, including statements regarding protocol staking (May 2025) and liquid staking (August 2025) and frequently asked questions issued in September 2026, and the Commission issued an interpretive release in March 2026 (Release No. 33-11412) addressing the application of the federal securities laws to certain crypto assets and activities, including protocol staking, these staff views and interpretive guidance are not rules, regulations or statements of the Commission, have no legal force or effect, and may be modified, revised or withdrawn at any time, and the Commission has not adopted formal rules as to whether particular digital assets constitute “securities” for purposes of the federal securities laws. Moreover, Bittensor’s staking model, in which staking does not validate or finalize transactions, may not fit squarely within the activities described in that guidance. If the Commission, a court of competent jurisdiction, or another regulatory authority were to determine that any of the digital assets we hold, or transactions involving those assets, constitute “investment securities,” such a determination could result in our being deemed to meet the definition of “investment company” under the 1940 Act if the portion of our assets that consists of investments in our Cryptocurrency exceeds the 40% limit prescribed in the 1940 Act, which would subject us to significant additional regulatory requirements that could have a material adverse effect on our business and operations and may also require us to change the manner in which we conduct our business. If we were required to register as an investment company under the 1940 Act, we would become subject to extensive and restrictive regulatory requirements, including limitations on our capital structure and leverage, restrictions on transactions with affiliates, custodial and valuation requirements, governance obligations, and enhanced reporting and compliance obligations. Compliance with these requirements would impose substantial costs, divert management attention, and could materially and adversely affect our business, financial condition, and results of operations.

Moreover, our current business model is not designed to operate as a registered investment company, and registration may not be feasible. The Commission has previously indicated that certain digital assets may be considered securities depending on their structure and use. Such determinations are highly fact-specific. Future developments could change the legal status of digital assets that we may hold, requiring us to comply with securities laws. Further, state regulators may conclude that the digital assets we hold are securities under state laws, requiring us to comply with state-specific securities regulations. States like California have stricter definitions of “investment contracts” than the Commission, increasing the risk of additional regulatory scrutiny. Such state-level determinations could subject us to additional regulatory obligations, enforcement actions, or limitations on our activities.

If any of our Cryptocurrencies are determined to be investment securities for purposes of the 1940 Act, we may be required to change our operations, wind down our operations, or register as an investment company under the 1940 Act. We could take steps to reduce our Cryptocurrency holdings as a percentage of our total assets, which may include, among others, selling Cryptocurrency that we might otherwise hold for the long term and deploying our cash in assets that are not considered to be investment securities under the 1940 Act, in which case we may be forced to sell Cryptocurrency at unattractive prices. In addition, we may seek to acquire additional assets that are not considered investment securities under the 1940 Act, restructure our operations, or incur indebtedness, issue additional equity, or enter into other financing arrangements that may be dilutive or otherwise unattractive to our business. Any of these actions could have a material adverse effect on our results of operations and financial condition. Moreover, we can make no assurance that we would successfully be able to take the necessary steps to avoid meeting the definition of “investment company” under the 1940 Act and becoming subject to its requirements. If any of our Cryptocurrencies are determined to constitute securities for purposes of the federal securities laws, and if we are not able to come within an available exemption or exclusion under the 1940 Act, then we would have to register as an investment company and change the manner in which we conduct our business, which may not be feasible. In addition, such a determination could adversely affect the market price of our Cryptocurrency and in turn adversely affect the market price of our common stock. If the associated regulatory burdens or costs become too great, we may be required to materially modify or cease certain operations, and investors could lose all or a portion of their investment in us.

46

Table of Contents

​

We may need to pursue additional equity or debt financings to continue our TAO accumulation strategy.

Based on our current balance sheet, we may need to pursue additional equity or debt financings in order to continue accumulating TAO consistent with our treasury strategy. Although we previously announced a goal of acquiring $100 million of TAO, we have not established a specific target amount of TAO that we seek to hold, and we do not currently expect to measure our strategy against that previously announced amount. With uncertainty in the capital markets and other factors, such financing may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to invest in our operations and otherwise suffer harm to our business.

The emergence or growth of other crypto assets, including those with significant private or public sector backing, could have a negative impact on the price of TAO and adversely affect our business.

Our assets are concentrated in a single crypto asset, TAO. Accordingly, the emergence or growth of crypto assets other than TAO may have a material adverse effect on our financial condition. TAO remains significantly smaller than many other crypto assets by market capitalization and liquidity. TAO’s success hinges, in part, on Bittensor’s ability to compete effectively in the decentralized AI ecosystem. Direct competitors include SingularityNET (AGIX), Fetch.ai (FET), Ocean Protocol, and others. If these platforms gain broader adoption, due to better performance, more user-friendly tools, or superior incentives, TAO could lose market share and relevance.

In addition, there are numerous alternative crypto assets and many entities, including consortiums and financial institutions, that are researching and investing resources into private or permissioned blockchain platforms or crypto assets that do not rely on decentralized machine learning or proof-of-intelligence models like the Bittensor network. For example, in late 2022, the Ethereum network transitioned to a proof-of-stake mechanism for validating transactions that requires significantly less computing power than proof-of-work mining. The Ethereum network has completed another major upgrade since then and may undertake additional upgrades in the future. If the mechanisms for validating transactions in Ethereum and other alternative crypto assets are perceived as superior to Bittensor’s or as more attractive due to increased utility beyond Bittensor’s narrower focus, those crypto assets could gain market share relative to TAO.

Other alternative crypto assets that compete with TAO in certain ways include “stablecoins,” which are designed to maintain a constant price because of, for instance, their issuers’ promise to hold high-quality liquid assets (such as U.S. dollar deposits and short-term U.S. Treasury securities) equal to the total value of stablecoins in circulation. Stablecoins have grown rapidly as an alternative to non-pegged crypto assets such as TAO as a medium of exchange and store of value, particularly on crypto asset trading platforms. Additionally, central banks in some countries have started to introduce digital forms of legal tender. For example, China’s central bank digital currency (“CBDC”) project was made available to consumers in January 2022, and governments including the United States, the United Kingdom, the European Union, and Israel have been discussing the potential creation of new CBDCs. Whether or not they incorporate blockchain or similar technology, CBDCs, as legal tender in the issuing jurisdiction, could also compete with, or replace, TAO and other crypto assets as a medium of exchange or store of value. As a result, the emergence or growth of these or other crypto assets could cause the market price of TAO to decrease, which could have a material adverse effect on our business, prospects, financial condition, and operating results.

Risks Related to the Custodian and Prime Broker

We face additional risks related to our reliance on BitGo Prime LLC (as the Prime Broker) and BitGo Bank and Trust, N.A. (as the Custodian), which are affiliated entities, for trading, custody, and settlement of TAO.

We rely on the Prime Broker’s proprietary trading system and the Custodian’s custodial and settlement services for executing and settling transactions in TAO. The Prime Broker’s trading system is subject to technical failures, operational errors, interruptions, or cyber-attacks that could lead to transaction failures, settlement delays, or loss of assets. Although the Prime Broker and the Custodian maintain policies and procedures to mitigate these risks, there is no guarantee these safeguards will prevent disruptions or losses. Any operational failures could materially harm our ability to conduct business operations.

47

Table of Contents

​

Additionally, transactions executed through the Prime Broker’s trading system and settled via the Custodian’s settlement services are final and irreversible once completed. Upon confirmation of a trade, settlement occurs on a delivery-versus-payment basis, whereby the Prime Broker facilitates the simultaneous exchange of U.S. dollars from the Company’s custodial account maintained with the Custodian in consideration for the delivery of the corresponding TAO tokens to such account. This settlement mechanism is designed to mitigate counterparty risk by ensuring that the transfer of funds and digital assets occurs concurrently and that the Company’s TAO assets remain in the custody of the Custodian throughout the transaction lifecycle. If an error occurs (whether through human mistake, operational failure, or fraudulent activity) we may be unable to reverse or recover funds, resulting in potential significant losses. Except in cases involving fraud, gross negligence, or willful misconduct, the Custodian’s liability for direct damages arising from theft, operational errors, unauthorized access, or similar incidents may be limited to the fees paid or payable during the 6 months immediately preceding the incident. Both the Custodian’s and Prime Broker’s liability for direct damages caused by their gross negligence or willful misconduct may be limited to the value of the affected digital assets or fiat currency. The Prime Broker otherwise may not be liable for losses relating to theft, operational errors, unauthorized access, or similar incidents. Consequently, our recourse, including for losses of TAO held by the Custodian, Prime Broker, or their service providers, may be substantially limited.

While the Custodian is a national trust bank chartered and regulated by the Office of the Comptroller of the Currency, our crypto assets held by the Custodian are not insured by the FDIC, and neither the Custodian nor the Prime Broker is a broker-dealer or a member of the Securities Investor Protection Corporation (“SIPC”). Therefore, assets held by the Custodian are not subject to the protections enjoyed by depositors with FDIC-insured institutions or customers of SIPC-member broker-dealers. The Custodian has advised us that it maintains insurance policies in the amount of $250 million, in the aggregate, which are intended to cover the loss of client assets held by the Custodian in cold storage. This coverage is shared among all of the Custodian’s clients and is not allocated to our account. Accordingly, the amount available to cover any loss of our TAO would depend on the claims of other clients at the time. We understand that TAO that is staked, held in hot wallets, or pending trade settlement may not be covered, or may be covered only in part. We do not maintain our own insurance covering our TAO holdings. As of October 23, 2026, our digital assets were valued at approximately $22.0 million. The insurance maintained by the Custodian may not be available or sufficient to protect us from all possible losses or sources of losses. The Custodian’s insurance may not cover the specific type of loss experienced by us. In addition, the TAO insurance markets are limited, and the level of insurance maintained by the Custodian may be substantially lower than the value of our assets. While the Custodian maintains certain capital reserve requirements based on the value of the assets under custody (which may provide additional means to cover client asset losses), we cannot be assured that the Custodian will maintain capital reserves sufficient to cover actual or potential losses with respect to our crypto assets.

Additionally, the security of crypto assets held by the Custodian depends significantly on how effectively the Custodian safeguards private cryptographic keys associated with such assets. Although the Custodian uses both “hot” (online) and “cold” (offline) storage mechanisms designed to balance security and operational needs, any crypto assets stored in hot wallets may be at increased risk of theft, hacking, or unauthorized access compared to those held solely in cold storage. Furthermore, the Custodian’s private key management practices, security protocols, and operational controls may not fully prevent cybersecurity breaches, human errors, or other security failures, which could result in partial or total loss of our crypto assets. Moreover, in the event of an insolvency or bankruptcy of the Custodian in the future, given that the contractual protections and legal rights of customers with respect to crypto assets held on their behalf by third parties are relatively untested in a bankruptcy of an entity such as the Custodian in the crypto asset industry, there is a risk that our assets may be considered the property of the bankruptcy estate of the Custodian. We may be at risk of being treated as a general unsecured creditor of such entity and subject to the risk of total loss or significant impairment of the value of such assets.

Furthermore, the Prime Broker may engage in trading activities strictly as principal, meaning it may act as our direct counterparty rather than as an agent, fiduciary, or financial advisor. The Prime Broker may simultaneously engage in hedging transactions or market-making activities, potentially creating conflicts of interest, including scenarios where the Prime Broker’s market activities negatively impact pricing or liquidity in our transactions. We do not have full visibility into these market-making or hedging activities, and these activities could result in less favorable execution terms than we might obtain elsewhere. Additionally, the Custodian’s custodial and settlement services depend on complex proprietary technology platforms and APIs provided by affiliates and third-party service providers. We are entirely dependent on the reliability and security of this technology infrastructure. Any operational disruption at the Custodian, Prime Broker, or their third-party providers could lead to delays, transaction failures, asset losses, or increased vulnerability to security breaches. Regulatory scrutiny or enforcement actions directed at the Prime Broker or Custodian could also adversely impact their ability to offer services, force changes in business practices, or cause operational disruptions. Such events could materially impair our business activities, operations, and the value of our crypto assets held by the Custodian.

48

Table of Contents

​

Risks Related to Staking

Staking activities involve significant risks, including the risks of validator or counterparty failure, operational failures and the potential loss of TAO, which could materially and adversely affect our financial performance and the value of our crypto assets.

Staking TAO tokens exposes us to a variety of operational, economic, technological, and regulatory risks. Although staking can generate rewards, the process involves delegating our TAO tokens to a validator. Although the Bittensor protocol does not impose an unbonding period, custodial, validator or operational arrangements may restrict our immediate liquidity and ability to freely trade or use these tokens and, for 18 months from November 5, 2025, our ability to diversify validators for root subnet staking is limited because we agreed to delegate at least 90% of TAO subject to root subnet staking to Yuma. Any operational disruptions, cybersecurity breaches, or software errors affecting our staking providers, validators, or the underlying blockchain network, including failures of the protocol to effect on-chain staking distributions, may result in partial or total loss of our staked TAO. In addition, the Yuma Agreement limits our recourse to a sole remedy for missed rewards, which does not include reward optimization, and generally caps Yuma’s aggregate liability at $5,000.

Unlike traditional financial instruments, staking and on-chain reward distributions are often final and irreversible once executed, increasing the risk associated with potential human errors, operational failures, or malicious activities. Additionally, the underlying validator operations and staking infrastructure may be subject to technical vulnerabilities or exploits. A failure, security breach, or operational deficiency in validator performance or infrastructure could significantly reduce or eliminate staking rewards or result in economic penalties that adversely affect our financial condition. Under our agreement with Yuma, our primary contractual remedy for service shortfalls is recovery of missed rewards, subject to an aggregate $5,000 cap and an exclusion of consequential and similar damages.

We depend on third-party providers, such as our Custodian, and our validator, Yuma, to facilitate and manage our staking activities. If our Custodian or validator experiences financial distress, insolvency, cybersecurity incidents, or other operational failures, we may experience significant delays or difficulty recovering staked tokens, lose expected staking rewards, or incur permanent loss of the underlying staked assets. Additionally, third-party staking providers, including our Custodian and Yuma, may not maintain sufficient insurance coverage to protect us against all types of loss scenarios, leaving us potentially exposed to substantial economic risk. For a discussion of our staking program, see “Our Staking Program” in Part I, Item 2 of this Quarterly Report on Form 10-Q.

Staking activities may also subject us to regulatory uncertainty and evolving interpretations of securities, commodities, and financial services laws. Regulators may impose licensing, registration, reporting, or other compliance requirements on our staking activities, leading to increased legal and operational burdens, costs, or interruptions. Furthermore, we may be required to alter, limit, or cease staking activities altogether in response to future regulatory or enforcement developments. Our agreement with Yuma permits immediate termination if services cannot be performed in compliance with applicable law or due to heightened regulatory risk or changes in law that render continued involvement undesirable, illegal, or impracticable, which could result in sudden disruption or cessation of their staking services. Disputes are subject to confidential, binding arbitration with a class-action waiver, which may limit judicial remedies. With respect to staking activities, the Custodian’s or an affiliate’s liability for direct damages, including slashing penalties or missed staking rewards, is also limited. Specifically, liability for slashing penalties may be capped at staking service fees collected during the 6-month period prior to the relevant incident. Liability for missed rewards may be capped at staking service fees collected during the preceding 3-month period. The Custodian or an affiliate also may not be liable for blockchain protocol malfunctions, software bugs, third-party validator errors, or any staking-related losses below $1,000 USD.

Separately, our agreement with Yuma generally caps Yuma’s aggregate liability at $5,000, and Yuma disclaims consequential damages and is not liable for protocol-wide malfunctions or force-majeure events related to the blockchain. Moreover, if any on-chain or implied protocol terms conflict with the Yuma Agreement, the agreement prevails. As the Bittensor protocol evolves, this “paramountcy” may cause frictions with network norms or expectations and may limit our ability to rely on protocol-level terms if they diverge from our contract. The occurrence of any of these risks could materially impair our crypto asset holdings, adversely affect the financial performance of our business, and significantly diminish the value of our TAO tokens. Our ability to recover losses may be further limited by contractual liability caps, exclusive remedies, and arbitration provisions in our agreements with key providers.

49

Table of Contents

​

Our reliance on the Custodian and its third-party validator for TAO staking activities creates concentration and related risks.

We rely on the Custodian to facilitate our staking activities with respect to TAO tokens. Through its staking services, the Custodian holds and facilitates the staking of our TAO through a single third-party validator, Yuma. While we believe Yuma was selected due to its reputation for security, reliability, and operational performance, neither the Custodian nor Yuma guarantees staking rewards, uninterrupted service, or protection against all operational or security risks. Our staked TAO could be subject to loss, reduction, or impaired liquidity due to validator performance issues, slashing-like economic penalties (in the form of reduced or eliminated rewards), cybersecurity breaches, network disruptions, regulatory actions, or technical failures affecting the Custodian’s staking infrastructure or the Bittensor blockchain itself. Moreover, we do not control Yuma’s operational practices or technical infrastructure, and we have limited visibility into or control over the processes by which staking rewards are generated and allocated. Yuma may terminate services immediately due to changes in law or heightened regulatory risk, which could disrupt our staking without advance notice.

In addition, our reliance on a limited number of third-party providers, notably our primary Custodian and the validator Yuma, creates a concentration of operational risk. The failure, underperformance, insolvency, or malfeasance of any key provider could materially and adversely affect our assets and staking operations. Given our significant reliance on Yuma as our sole validator, disruptions affecting Yuma, such as downtime, operational deficiencies, cybersecurity breaches, or withdrawal from the market, could leave us unable to promptly identify or transition to an equivalent validator. In addition, for 18 months from November 5, 2025, the Yuma Agreement requires us to delegate at least 90% of TAO subject to root subnet staking to Yuma, which increases our concentration risk and may limit our ability to diversify or migrate quickly in response to performance or pricing changes. Yuma may assign its obligations to an affiliate or in connection with a change of control without our consent, which could change our counterparty risk profile. This could result in our TAO tokens remaining unstaked, thereby causing us to forego anticipated staking rewards, or forcing us to hurriedly redelegate our tokens, potentially leading to suboptimal returns or additional costs. Furthermore, any material changes in the terms or fee structures imposed by our staking providers, including increased commission rates, more restrictive withdrawal conditions, or diminished service quality, may significantly reduce our net rewards, making our staking activities financially less attractive.

Our reliance on a single validator, Yuma, and on the Custodian exacerbates our exposure to the operational, financial, and cybersecurity risks specific to these providers, analogous to counterparty risk in traditional financial services. Consequently, operational failures, security incidents, regulatory issues, or adverse business developments affecting the Custodian or Yuma could significantly harm our business, financial condition, and the value of our crypto asset holdings.

Our TAO staking relies on the Custodian and our Validator, and any future direct participation in subnet automated market maker (“AMM”) pools, would expose us to additional liquidity, market, and operational risks beyond our direct control.

We stake TAO tokens through arrangements facilitated and managed by the Custodian and its selected validator, Yuma. We do not currently engage directly in dTAO Staking or participate directly in subnet AMM pools and have no present plans to do so, but may do so in the future. Should we do so in the future, the economic viability of subnet AMM pools remains largely unproven, and these pools are subject to experimental and rapidly evolving technological and regulatory environments. Any adverse event affecting these AMM pools, including but not limited to unfavorable market conditions, liquidity shortages, smart contract vulnerabilities, cybersecurity breaches, or operational failures, could result in significant financial losses, impairment of the liquidity or value of our staked TAO, or even total loss of our crypto assets.

Our investments in subnet funds managed by Yuma Asset Management give us indirect exposure to Bittensor subnet tokens, which could result in losses.

We hold about 7.5% of each of Yuma Subnet Composite Onshore Fund, L.P. and Yuma Large Cap Subnet Onshore Fund, L.P., which invest in Bittensor subnet alpha tokens. The value of our interests depends on those tokens, which can be significantly more volatile and less liquid than TAO. In the three months ended June 30, 2026, the fair value of our interests decreased by $318,870. Yuma Asset Management, not us, decides which subnets the funds hold. Our interests are not redeemable until December 31, 2026, after which we may request redemption only at the end of a calendar quarter, subject to the funds’ approval. Because Yuma Asset Management is an affiliate of Yuma, which operates the validator to which we delegate our TAO, problems affecting that group could affect both our staking and these investments. Yuma Asset Management’s interests and fees may not align with ours, and we do not control the funds’ investment decisions.

50

Table of Contents

​

We have no present plans to stake directly on individual subnets. If we were to do so in the future, our positions would be held in alpha tokens rather than TAO. Converting alpha back to TAO could require exchanging at a significantly worse rate than we paid, particularly for large positions or in thin pools. A subnet’s share of network emissions can decline, and a subnet can be deregistered. Any of these events could reduce the value of our holdings and our staking income and adversely affect the value of our common stock.

Risks Related to Our Media Platform

We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.

We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in the operation of our media platform, The TAO Daily and in our day-to-day operations. In connection with the operation of The TAO Daily, we may collect and use a variety of personal data, such as name, mailing address, email addresses, and phone number. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of personal data could result in significant liability under state (e.g., state breach notification laws), federal, and international law (e.g., the GDPR) and may cause a material adverse impact to our reputation and potentially disrupt our business.

In addition, the computer systems of various third parties on which we rely, and other contractors, consultants and law and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business.

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On July 6, 2026, we issued 75,000 warrants to a consultant in exchange for strategic planning for potential artificial intelligence business, which warrants are exercisable at an exercise price of $3.85 per share for a term of five years from the date of issuance, and, pursuant to the anti-dilution provisions of the Series E Warrants, an additional 588,098 Series E Warrants to existing holders. During the quarter, holders converted 1,946.75 shares of Series E Convertible Preferred Stock into 505,650 shares of Common Stock.

On September 8, 2026, we issued 1,123 shares of Common Stock to a consultant in exchange for investor relations services.

51

Table of Contents

​

On November 13, 2026, we amended the warrants to purchase an aggregate of 1,200,000 shares of Common Stock previously issued to the Z-List Media, Inc. under a consultant agreement, solely to reduce the exercise prices thereof, as follows: (i) the warrant to purchase 400,000 shares of Common Stock, from $4.00 to $2.10 per share; (ii) the warrant to purchase 200,000 shares of Common Stock, from $6.00 to $4.00 per share; (iii) the warrant to purchase 200,000 shares of Common Stock, from $8.00 to $6.00 per share; and (iv) the warrant to purchase 400,000 shares of Common Stock, from $12.00 to $8.00 per share. The number of shares underlying the warrants, the vesting and forfeiture conditions, the expiration dates and all other terms of the warrants remain unchanged, and the Amendment does not provide for any new or additional grant of warrants or other additional compensation to Z-List Media, Inc.

The foregoing transactions did not involve any underwriters or any public offering. The issuances were exempt from registration under Section 4(a)(2) of the Securities Act and, for the conversions, Section 3(a)(9) of the Securities Act. The recipients represented their intentions to acquire the securities for investment only and not with a view to, or for sale in connection with, any distribution thereof, and appropriate legends were affixed to the securities issued in these transactions. The recipients received or had, through their relationships with us, adequate access to information about us.

​

Item 3. Defaults upon Senior Securities.

None.

​

Item 4. Mine Safety Disclosures.

Not applicable.

​

52

Table of Contents

​

Item 5. Other Information.

Amendment to Altucher Consulting Agreement

On June 8, 2025, TAO Synergies Inc. (the “Company”) entered into a consulting services agreement (the “Altucher Consulting Agreement”) with James Altucher and Z-List Media, Inc., a company wholly owned by Mr. Altucher (together, the “Consultant”). Under the agreement, Mr. Altucher assists the Company with, among other things, crypto portfolio management, investor relations, strategic planning, deal flow analysis and advice on sector growth initiatives. The Altucher Consulting Agreement had an initial term of one year. On November 13, 2026, the Company and the Consultant entered into Amendment No. 1 to the Altucher Consulting Agreement (the “Consulting Agreement Amendment”). The Consulting Agreement Amendment extends the term of the Altucher Consulting Agreement through June 8, 2029, unless earlier terminated in accordance with its terms or by mutual written consent of the parties. Except as described above and under “Amendment to Consultant Warrants” below, the terms of the Altucher Consulting Agreement remain unchanged and in full force and effect.

This description of the Consulting Agreement Amendment is not complete. It is qualified in its entirety by the full text of the Consulting Agreement Amendment, which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

In consideration of the extension of the term, the Consulting Agreement Amendment provides that, effective as of its effective date, the Company and the Consultant will amend each of the warrants previously issued to the Consultant under the Altucher Consulting Agreement solely to reduce the exercise price per share of Common Stock as follows: (i) the warrant to purchase 400,000 shares of Common Stock, from $4.00 to $2.10 per share; (ii) the warrant to purchase 200,000 shares of Common Stock, from $6.00 to $4.00 per share; (iii) the warrant to purchase 200,000 shares of Common Stock, from $8.00 to $6.00 per share; and (iv) the warrant to purchase 400,000 shares of Common Stock, from $12.00 to $8.00 per share. The number of shares underlying each warrant, the vesting and forfeiture conditions, the expiration date and all other terms of the warrants remain unchanged, and the amended warrants do not constitute a new or additional grant of warrants.

Grant of Stock Awards and Stock Options

On November 13, 2026, the Board of Directors of the Company, approved the following grants under the Company’s Amended and Restated 2020 Equity Incentive Plan (the “2020 Plan”) to officers of the Company: (i) to Joshua N. Silverman, Executive Chairman, 131,250 fully vested shares of Common Stock (the “Stock Awards”), and fully vested non-qualified stock options to purchase 131,250 shares of Common Stock, and (ii) to Robert Weinstein, Chief Financial Officer, Treasurer, Secretary and Executive Vice President, fully vested non-qualified stock options to purchase 50,000 shares of Common Stock (together with the options granted to Mr. Silverman, the “Options”). The Options have an exercise price of $2.10 per share. The Stock Awards and Options are otherwise subject to the terms of the 2020 Plan and the Company’s form of stock award agreement or option agreement, as applicable.

Grant of Subsidiary Stock Awards

On October 21, 2026, the Company formed AlphaSynergies.ai (the “Subsidiary”), a Nevada corporation and wholly owned subsidiary of the Company, by filing Articles of Incorporation with the Nevada Secretary of State. The Subsidiary was formed for the purpose of facilitating the Company’s expansion into the AI business leveraging off its existing cryptocurrency treasury strategy. The Subsidiary is authorized to issue 12,000,000 shares of capital stock, consisting of 10,000,000 shares of common stock, par value $0.0001 per share, and 2,000,000 shares of preferred stock, par value $0.0001 per share.

On November 13, 2026, the Board of Directors of the Company, in its capacity as sole stockholder of the Subsidiary, approved the subsidiary’s grant of fully vested shares of Subsidiary common stock (the “Subsidiary Stock Awards”), in consideration of services rendered and to be rendered to the Subsidiary, as follows: Joshua N. Silverman, Director, Chief Executive Officer, President and Secretary of the Subsidiary and Executive Chairman of the Company, 75,000 shares; Bruce T. Bernstein, Director of the Subsidiary and the Company, 25,000 shares; Robert Weinstein, Chief Financial Officer and Treasurer of the Subsidiary and Chief Financial Officer of the Company, 12,500 shares; and James Altucher, consultant, 100,000 shares.

As of November 16, 2026, the Subsidiary had 1,212,500 shares of common stock outstanding.

​

53

Table of Contents

​

Because Messrs. Silverman, Bernstein and Weinstein are directors and/or executive officers of the Company, and Messrs. Bernstein and Silverman also serve as directors of the Subsidiary, the Subsidiary Stock Awards were approved by the Board of Directors of the Company, including its disinterested members.

​

​

Rule 10b5-1 Trading Plans

During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

​

54

Table of Contents

​

Item 6. Exhibits.

​

Exhibit Number

  ​ ​ ​

​

3.1.1

​

Amended and Restated Certificate of Incorporation of TAO Synergies Inc. (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 10, 2020).

​

​

​

3.1.2

​

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Synaptogenix, Inc. (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 4, 2024).

​

​

​

3.1.3

​

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Synaptogenix, Inc. (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 27, 2025).

​

​

​

3.2

​

Amended and Restated Bylaws of TAO Synergies Inc. (incorporated by reference from Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2025).

​

​

​

3.3

​

Certificate of Designations of Series D Convertible Preferred Stock of Synaptogenix, Inc. (incorporated by reference from Exhibit 3.1 to the Registrant’s Registration Statement on Form S-3 filed with the SEC on July 11, 2025).

​

​

​

3.4

​

Certificate of Designations of Series E Convertible Preferred Stock of Synaptogenix, Inc. (incorporated by reference from Exhibit 3.1 to the Registrant’s Registration Statement on Form S-3 filed with the SEC on November 12, 2025).

​

​

​

10.1*

​

Amendment No. 1 to Consulting Services Agreement, dated as of November 13, 2026, by and among TAO Synergies Inc., Z-List Media, Inc. and James Altucher.

​

​

​

31.1*

​

Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

​

​

​

31.2*

​

Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

​

​

​

32**

​

Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

​

​

​

101*

​

The following financial information from this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss); (iii) the Condensed Consolidated Statements of Changes in Stockholders’ Equity; (iv) the Condensed Consolidated Statements of Cash Flows; and (v) the Notes to Condensed Consolidated Financial Statements.

​

​

​

104*

​

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith.

​

** The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of TAO Synergies Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.

​

​

55

Table of Contents

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

 

TAO Synergies Inc.

 

 

Date: November 16, 2026

By:

/s/ Joshua N. Silverman

 

Joshua N. Silverman

 

 

Executive Chairman of the Board of Directors

 

 

(principal executive officer)

 

 

Date: November 16, 2026

By:

/s/ Robert Weinstein

 

 

Robert Weinstein

 

 

Chief Financial Officer, Executive Vice President, Secretary and Treasurer

​

​

(principal financial officer and principal accounting officer)

​

56

Keep reading